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In disease states such as cancer, endocrine and paracrine signals from adipose tissue 
contribute to cancer progression and drug resistance. Young individuals diagnosed with 
estrogen receptor-alpha positive (ER-a+) breast cancer have an observed increase in 
resistance to endocrine therapies. This suggests that an alternative estrogen signaling 
pathway is active within these tumors. Despite this, the effects of stromal age on the 
endocrine response in breast cancer is not well known. Here, we review and highlight the 
involvement of the stromal age in both tumorigenesis and physiological wound healing. 
To identify specific differences between young and aged ER-a+ breast tumors, RNA 
sequencing data was obtained from The Cancer Genome Atlas (TCGA). Analysis 
revealed enrichment of matrix and paracrine factors in young (<40 years old) patients 
compared to aged (>65 years old) tumor samples. Analyzing cell infiltrate of young and 
aged ER-a+ breast tumors revealed significant differences in several immune cell 
populations, however, there were no differences in MSC and adipocyte infiltrate between 
young and aged tumors. Based on these results, we next sought to determine if stromal 
cells exhibited age-dependent differences. To determine if the age of tumor stroma 
differentially regulated the ER-a+ tumor microenvironment (TME), adipose-derived 
stem/stromal cells (ASCs) from healthy young and aged donors were evaluated for 
alterations in matrix production and paracrine factors. Results demonstrated that young 
and aged ASCs were neither phenotypically different, nor did they demonstrate 
alterations in matrix production. Analysis of paracrine factors demonstrated that young 
and aged ASCs had differences in pro-inflammatory cytokines. Paracrine factors from 
young ASCs enhanced the ER-a regulated genes progesterone receptor (PR) and 
stromal-derived factor 1 (SDF-1) in the MCF-7 ER-a+ breast cancer cell line. Additionally, 
western blot analysis demonstrated increased activation of p-ER ser167 in the MCF-7 
cell line treated with young ASC paracrine factors. These results are important in 
understanding the mechanisms of estrogen receptor signaling in young breast cancer 




CHAPTER 1. BACKGROUND AND SIGNIFICANCE 
 
 
1.1 Breast Cancer and Tumor Microenvironment  
 
Breast cancer is a heterogeneous disease that includes several biological subtypes 
that exhibit different clinical behaviors and treatment responses1. These tumors express 
the estrogen receptor (ER) and/or progesterone receptor (PR). Together, these comprise 
the luminal subtype and represent approximately ~70% of all breast cancer cases2, 3. 
Hormone receptor positive breast cancer can be further subdivided into luminal A and 
luminal B. Luminal A accounts for 30-40% of all invasive breast cancers, whereas luminal 
B accounts for 20-30%4. Other subtypes of breast cancer include human epidermal 
growth factor receptor 2 (HER2) enriched and basal-like/triple negative (Table 1.1). The 
presence of PR in breast tumors is an important indicator for endocrine therapy 





1.1.1 ER-a+ Breast Cancer: Biology and Treatment Options 
 
Estrogen plays an important role in the development and progression of breast 
cancer. ER is one of the most significant prognostic biomarkers in breast cancer and 
possesses a dual role as both a nuclear hormone receptor and transcription factor. ER 
has two subtypes: ER-a and ER-b. ER-a is present mainly in mammary glands, uterus, 
bone, male reproductive organs, and liver. On the other hand, ER-b is expressed mainly 
in the bladder, colon, and the immune system7. Both subtypes are expressed in 
adipose, prostate, and ovarian tissue. The activation of the ER-a receptors are 
responsible for most estrogen effects on normal breast tissue and cancerous breast 
tissue, leading to hormone-dependent tumor growth8, 9. ER-a can be activated via 
classical estrogen ligand-binding or through a complex network of tyrosine kinase 
membrane receptors and their downstream targets (Fig 1.1). The classical mechanism 
of estrogen signaling is also known as direct genomic signaling. Upon binding to 
Table 1.1. Classification of molecular subtypes of breast cancer. Table reproduced from 
data from Fragomeni et al., 2018.   
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estradiol, the nuclear estrogen receptor ER-a behaves as a transcription factor and 
translocates from the cytoplasm to the nucleus10, 11. The complex then binds to estrogen 





Receptor tyrosine kinases (RTKs) including epidermal growth factor receptor (EGFR), 
insulin-like growth factor 1 receptor (IGF1R), and HER2 can stimulate ER translocation, 
thus regulating gene expression and controlling cell growth, proliferation, and survival13. 
The non-genomic function of ER-a and its ability to bind to and activate transcription 
factors adds to the complexity of ER-a signaling. The non-genomic actions of estrogen 
lead to a more rapid signaling response. After the discovery of the G Protein-Coupled 
Estrogen Receptor (GPER1), a membrane bound estrogen receptor that induces a fast 
estrogen-mediated activation of extracellular signal-regulated kinases (ERKs), the 
mechanism of estrogen expanded beyond direct target gene transcription and protein 
synthesis14, 15. The non-genomic actions of estrogen involve the activation of several 
protein-kinase signaling cascades including: the phospholipase C (PLC)/protein kinase 
C (PKC) pathway, RAS/RAF/MAPK cascade, phosphatidyl inositol 3 kinase (PI3K)/AKT 
Figure 1.1. Estrogen receptor (ER) signaling pathway. (a) 
Classic ER signaling (b) The ER activation through 
receptor tyrosine kinases (RTKs) (c) Nongenomic functions 
of ER. Figure reproduced with permission from Macmillan 
Publishers Ltd.: Musgrove and Sutherland, 2009. 
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kinase cascade, and cAMP/protein kinase A (PKA) signaling pathway16-21. These 
signaling pathways subsequently activate transcription factors such as the nuclear 
factor-kappa B (NF-kB) complex, which translocates to the nucleus and to their cognate 
DNA binding sites. Estrogen receptors can also be activated in the absence of 
estrogens or receptor agonists via a ligand-independent signaling mechanism22-25. 
Activation occurs via phosphorylation of specific residues (i.e. serine or tyrosine) on the 
receptors or by association with coregulators. The coregulators encompass a variety of 
regulatory molecules including PKA, PKC, MAPK cascade components, inflammatory 
cytokines (IL-2), cell adhesion molecules (Heregulin), cell cycle regulators (RAS), and 
peptide growth factors (EGF, IGF-1, TGFb)25.  ER-a activation and signaling is best 
interpreted through ER-a response genes. PR is an important target gene of ER-a and 
thus behaves as a downstream indicator of estrogen action26.  Similar to ER-a, there is 
also extensive crosstalk between PR and signal transduction pathways that are not only 
required for mammary gland development, but are also often elevated in breast cancer. 
Historically, PR was thought to be a tightly regulated target of ER-a; however, studies 
have shown that growth factors such as IGF-1 downregulate PR activity through the 
PI3K/AKT/mTOR signaling pathway independent of ER-a activity27. Furthermore, the 
downregulation of PR activity signifies increased growth factor activity28. The ER-a 
independent function of PR and the complex crosstalk of multiple signal transduction 
pathways with ER-a and PR increase the difficulty to provide targeted therapy for breast 
cancer patients.  
In ER-a+ breast cancers, active ER-a signaling drives cell proliferation, thus 
making ER-a heavily exploited as the target for treatment. Inhibitors of the ER-a pathway 
are categorized based on their mechanism of action: 1) compounds that decrease 
endogenous estrogen production (aromatase inhibitors-AI and gonadotropin-releasing 
hormone agonists or 2) compounds that directly antagonize ER-a (selective estrogen 
receptor modulators and selective estrogen receptor degraders-SERMs and SERDs)29. 
Despite their positive therapeutic effect on ER-a+ breast cancers, many of the ER-a 
antagonists have become ineffective due to endocrine resistance. A large number of 
patients with ER-a+ breast cancers do not respond to endocrine therapy either due to de 
novo or acquired resistance13, 30-32.  As described above, many different factors including 
growth factors, cytokines, and estrogens may contribute to and induce ER-a signaling 
cascades. The complexity of endocrine signaling makes it difficult to define, identify the 
root causes, and generate alternative treatment options. Clinical studies have described 
several mechanisms for the resistance to endocrine therapies33, 34. The variance in 
mechanisms makes the treatment strategy increasingly difficult and dependent on the 
context. The impact of the tumor microenvironment (TME) plays a significant role in the 
development and progression of breast cancer and is a contributing source for many of 
signaling molecules that can modulate ER-a signaling. It should be considered as a key 







1.1.2 The Tumor Microenvironment (TME) 
 
The TME is a heterogeneous network consisting of different cellular types and 
extracellular components. The cellular and extracellular network communicates with the 
tumor cells, creating an intricate signaling system. The “seed and soil” hypothesis 
suggests that the host microenvironment (the soil) is required for optimal growth of the 
tumor cells (the seed)35. This hypothesis has driven a shift from primary focus on the 
tumor cells to the characterization and analysis of the interactions of the tumor stroma 
with the tumor cells. The communication between the host stroma and tumor cells 
drastically impacts tumor growth and progression. Dvorak describes tumors as “wounds 
that do not heal” and emphasizes the similarities of normal wound healing to tumor 
stromal generation36. Similar to the phases of wound healing, tumor stromal generation 
exhibits neoangiogenesis, infiltration of fibroblasts and immune cells, and remodeling of 
the extracellular matrix (ECM) (Table 1.2).  Tumors recruit supporting cells from the local 
host stroma which promote ECM remodeling, cellular migration, neoangiogenesis, 
invasion, drug resistance, and evasion of immunosurveillance through the production of 
growth factors, chemokines, and cytokines37. Supporting cells include fibroblasts, 
myofibroblasts, endothelial cells, adipocytes, mesenchymal stem cells (MSCs), and 
various immune cells38-40. The infiltration of the cellular recruits is in response to tumor-
driven inflammation41. Chronic inflammation aids in shaping the TME and has been 
referred to as a host reaction to the tumor; however, it is more appropriate to characterize 
this response as a tumor promoting reaction41. A contributing factor to the inflammatory 
nature of the tumor infiltrates is the self-induced hypoxic environment. Early in tumor 
development, tumor cells activate hypoxia-responsive genes, which in turn stimulate the 
influx of inflammatory cells into the TME. Hypoxia activates the NF-kB signaling pathway, 
which plays a key role in signaling of cancer cells and tumor-infiltrating leukocytes42-44. 
NF-kB activation leads to the secretion of tumor necrosis factor-alpha (TNF-a) and other 
pro-inflammatory cytokines that drive the expression of cytokine genes responsible for 
cell proliferation. In response to the pro-inflammatory cytokine cascade, tumor and 
stromal cells produce a wide array of biological mediators that help maintain the cell 
proliferation and differentiation, matrix remodeling, neoangiogenesis, and cell 
migration/recruitment necessary for tumor growth. MSCs, one of the supporting cell 
populations of the tumor stroma, are of particular interest in the development and 
progression of breast cancer because of their release of cytokines and growth factors that 
enhance the inflammatory nature of tumors.  
Some MSCs, such as ASCs, have a natural proclivity to induce inflammation 
because their tissue of origin, adipose tissue, actively participates in physiologic and 
pathologic processes including immunity and inflammation. As the largest endocrine 
organ, adipose tissue releases a variety of pro-inflammatory and anti-inflammatory factors 
including the adipokines leptin (LEP) and adiponectin (ADIPOQ), as well as cytokines 
and chemokines such as TNF-a, interleukin 6 (IL-6), and monocyte chemoattractant 
protein 1 (MCP-1)45. Further discussion of the effect of MSCs on breast cancer 
development and progression is presented in section 1.2.  
The TME and its stromal cell population heavily influences breast cancer initiation 
and growth; however, several key elements are missing from the picture. Included within 
this is the effect of patient demographics. Studies have examined the role of body mass 
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index (BMI) on the TME and breast cancer progression, but have yet to consider the role 
of other patient demographics including age on the nature of the TME46, 47. The 
characterization of MSCs based on age and the role it plays in breast cancer development 
and progression has yet to be fully elucidated.  
 
1.2 Breast Cancer and Stem Cells  
 
As previously described in section 1.1, the tumor stroma is composed of a 
heterogeneous cell population that includes MSCs. The secretion of factors such as MCP-
1 and SDF-1 from the tumor’s cancer and inflammatory cell population recruits MSCs to 
the TME. After recruitment to the site of inflammation, MSCs become part of the tumor 
stroma and facilitate tumor growth. Studies have shown that MSCs not only stimulate 
tumor growth, but also promote angiogenesis and increase cancer cell invasion48-50. 
Breast cancer cell-activated MSCs secrete a large panel of cytokines, chemokines, and 
growth factors that in turn enhances breast cancer cell proliferation in an MSC/breast 
cancer cell reciprocal feedback loop51. The dynamic relationship between MSCs and 
cancer cells not only influences tumor growth, aggressiveness, and metastatic spread, 
but may also function as barrier for therapeutic intervention in breast cancer patients.  
 
1.2.1 Adipose-Derived Stem/Stromal Cell Biology 
 
ASCs, a subset of mesenchymal stem cells isolated from adipose tissue, have 
gained clinical interest due to both their abundant and readily available resources, and 
because of their similarity to other established stem cell lines52. ASCs possess the ability 
to self-renew and differentiate toward adipogenic, osteogenic, and chondrogenic lineages 
in response to specific stimuli52-55. ASCs promote damaged tissue recovery by 
proliferating and differentiating cells; however, their capacity to supply growth factors and 
cytokine to tissue repair may be of even greater importance56. Studies have shown that 
ASCs are superior in secretion of bioactive factors that may stimulate cell proliferation, 
differentiation, and migration of cell types including fibroblasts, endothelial cells, and 
epithelial cells57. ASCs release a wide range of trophic factors including chemokines,  






angiogenic/anti-apoptotic/anti-scarring factors56, 58 (Fig 1.2, Table 1.2). Hsiao et al. found 
that out of all MSC populations, ASCs were the most optimal for promoting angiogenesis  
and had higher levels of insulin like growth factor 1 (IGF-1), vascular endothelial growth 
factor D (VEGF-D), and hepatocyte growth factor (HGF)59, 60. These growth factors have 
both angiogenic and anti-apoptotic properties and are associated with endothelial cell 
growth and survival61. In addition to growth factors, ASCs also secrete a variety of 
cytokines and chemokines. Many of the secreted cytokines including interferon gamma 
(IFN-g), IL-1b, IL-17, IL-8, and TNF-a are pro-inflammatory in nature62. Other MSC-
secreted inflammatory chemokines including MCP-1 and CCL5 promote tumor 
aggressiveness and support tumor-supporting effects in TME cells. Furthermore, these 
chemokines play a pivotal role in the growth and metastasis of cancers, including breast 
cancer60, 63-67. Previous studies have shown that stromal-derived factor 1 (SDF-1), 







Table 1.2. Trophic and immunomodulatory factors secreted by MSCs. Table 




but it is also contributes to primary breast tumorigenesis and promotes hormone 
independent growth of the hormone-dependent breast carcinoma cell line MCF-768-70.  In 
contrast to a tumorigenic role, IL-8, MCP-1, CCL5, and SDF-1 are also targeted to 
improve wound healing.  IL-8 acts as a potent neutrophil attractant during the early stages 
of wound healing71. ASCs also release CCL5 and MCP-1, which recruits macrophages to 
the wound site72. In the proliferation phase of wound healing, ASCs secrete SDF-1 to 
recruit more ASCs to the site, which then differentiate into endothelial cells and fibroblasts 
to form the granulation tissue73, 74. Similar to ASCs, “tumor wounds” secrete cytokines 
and chemokines that aid in myeloid cell recruitment. After reaching the tumor site, many 
of these myeloid cells differentiate into immunosuppressive and angiogenic phenotypes 
that help to facilitate tumor growth. This prevents tissue restoration and allows the tumor 
to remain in the proliferative phase of the wound healing process. Analogous to a tumor, 
the chemokine and cytokine milieu released by ASCs can also instigate the formation of 
a non-healing “tumor wound”.  The dual nature of ASCs as both regenerative and pro-
oncogenic has earned them their reputation as a “double-edged sword”75, 76. Despite their 
Figure 1.2. Paracrine effects of cultured MSCs. The secretion of a 
broad range of bioactive molecules is now believed to be the main 
mechanism by which MSCs achieve their therapeutic effect and it can 
be divided into six main categories: immunomodulation, anti-apoptosis, 
angiogenesis, support of the growth and differentiation of local stem 
and progenitor cells, anti-scarring and chemoattraction. Figure 
reproduced with permission from da Silva Meirelles et al., 2009. 
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therapeutic potential, ASCs also pose a risk for the development and progression of 
tumors, as well as the recurrence of different types of cancer77-79 Studies have shown that 
ASC paracrine signaling plays a crucial role in the breast cancer TME and aids in tumor 
progression.  
 
1.3 Cancer and Wound Healing  
 
1.3.1 Parallels between Cancer and Wound Healing  
 
Aging entails the progressive, generalized impairment of physiological function, 
resulting in a poor response to environmental challenges and expanding risk of disease 
and death. Although susceptibility to chronic diseases such as cancer and impaired 
wound healing increases with age, the potency of wound and cancer response appears 
to be far greater in younger individuals. Studies have shown that younger individuals 
experience more aggressive cancers with lower survival rates in both breast and 
colorectal cancers80-83. The physiological wound healing response occurs via a tightly 
regulated series of overlapping phases involving numerous cell types, tissues, secretory 
factors, and proteolytic enzymes. Tumors, which can be characterized as an 
unconventional, non-healing wound, hijack the body’s wound response to create an ideal 
environment for tumor growth and progression. Studies have shown that all major 
pathways activated in wound healing are also active in cancers84-87. A study by Chang et 
al. revealed that the gene expression pattern of serum-treated fibroblasts exhibiting a 
wound healing response parallels that of human carcinomas88. Molecular features that 
characterize the wound-like phenotype are observed at an early clinical stage, persist 
during treatment, and predict risk of metastasis and death in breast, lung, and gastric 
carcinomas88 89, 90. Riss et al. have shown that 77% of genes expressed in a model of 
renal repair and regeneration were also expressed in renal cancer. Many of these genes 
are active pathways common to cancer and repair including cell proliferation, growth, 
metabolism, and defense.91 In a study by Groessl et al., cancer-associated fibroblasts 
from breast cancer biopsies displayed a wound healing signature92. Multiple sources have 
emphasized that inflammation, an essential phase of the wound healing response, is a 
key player in cancer progression84, 93, 94.  An overabundance of specific inflammatory cell 
types, as discussed in detail below, results in the transformation of an acute wound into 
a chronic wound, and non-cancerous tissue into tumors95-97. Similar to a wound, tumors 
also secrete various trophic factors that aid in the recruitment of multiple cell types 
including MSCs.  
 
1.3.2 Stromal Contribution to Cancer and Wound Healing 
 
BMSCs and ASCs respond to damaged tissues and organs and secrete cytokines, 
chemokines, and growth factors to mediate the physiological wound healing response98-
100. The therapeutic effect of MSCs during wound repair can be attributed to the release 
of these trophic factors, which promote angiogenesis, cell recruitment, differentiation, 
proliferation, and ECM formation101-103. Kilroy et al. characterized the cytokine profile of 
MSCs showing that the use of the pro-inflammatory ligand lipopolysaccharide (LPS), an 
immune stimulating glycolipid produced by gram-negative bacteria. Results from this 
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study demonstrated that MSCs released angiogenic HGF and VEGF, and hematopoietic 
(IL-7, GM-CSF)) cytokines, in addition to secreting a number of pro-inflammatory 
cytokines (IL-6, IL-8, IL-11, TNF-a)104. The paracrine behavior of MSCs also poses both 
immunomodulatory and immunosuppressive effects that impacts the wound healing 
process. As a response to both injury and inflammation, the release of prostaglandin E2 
(PGE2) by MSCs results in the upregulation of interleukin 10 (IL-10) and decrease in 
TNF- a and interleukin 12 (IL-12) secretion from dendritic cells, leading to a shift from a 
more pro-inflammatory Th1 subtype to an anti-inflammatory Th2 subtype105. MSCs 
attenuate the release of inflammatory mediators from macrophages and modulate the 
proliferation, differentiation, and immunoglobulin secretion of B cells105-107. The release of 
cytokines that both support and delay tissue recovery pose many questions concerning 
the role of MSCs in wound healing and tumorigenesis. Evidence has shown that MSCs 
not only aid in the healing of conventional wounds, but are also linked to non-healing 
tumor wounds. Similar to wound response, MSCs respond to tumors by homing to the 
tumor site to mediate the physiological wound healing response. Both newly recruited 
and resident MSCs work together to accelerate the tumor “wound healing”108. Similar to 
their role in physiological wound healing, MSCs assist in regulating tumor-associated 
immune responses. After instruction by the TME, MSCs secrete cytokines and 
chemokines that exaggerate tumor-associated inflammation via the recruitment of 
multiple immune cell types109-113(Table 1.3). In addition to inducing inflammation, MSCs 
can also suppress the adaptive immune response in the TME through the release of  
effector molecules including nitric oxide (NO) and indoleamine 2,3-dioxygenase (IDO)114-
118. Although there is a substantial body of work dedicated to the role of BMSCs in wound 
healing and tumorigenesis, ASCs and their impact on wound healing and tumorigenesis 
will be the sole focus of this dissertation. For more information regarding BMSCs, please 





Table 1.3. The effect of MSCs on immune cell infiltrate.  
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1.3.3 The Impact of Aging on Cancer and Wound Healing  
 
Age has been hypothesized as a significant contributing factor in both wound 
healing and cancer, yet few studies have focused on the characterization of MSCs on the 
basis of age. As illustrated by Dvorak, the tumor response has striking similarities to the 
physiological response to tissue injury85. Based on this relationship, age could play a 
crucial role in both responses. Young individuals exhibit a more exuberant wound healing 
response compared to aged. The impact of aging is observed in all phases of the wound 
healing process122. The disruption of any step in one of the phases in wound repair can 
lead to a 20-60% delay in healing123. Fully understanding the dynamic interplay of stromal 
age and wound healing response could offer insight into why young patients with some 
cancer subtypes present with a poorer prognosis and greater mortality than aged124. In 
this dissertation, we investigated the role of MSCs in the physiological wound healing 
process, their response to non-healing tumor wounds, and the impact of age on the MSC 
response to both wound types.  
 
1.4  ASC Response to Tumors and Wounds  
 
1.4.1 Physiological Wounds Vs. Tumor Wounds  
 
The wound healing process is characterized by a dynamic series of overlapping 
phases involving numerous cell types, tissues, cytokines, chemokines, growth factors, 
and proteolytic enzymes125. Cellular activities including proliferation, migration, and ECM 
synthesis are tightly regulated in the wound healing phases of hemostasis (coagulation), 
inflammation, proliferation (formation of granulation tissue), and tissue remodeling (scar 
formation)126, 127 (Fig. 1.3). Hemostasis is characterized by fibrin clot formation, platelet 
activation, and release of inflammatory mediators. The release of numerous cytokines, 
chemokines, and growth factors including PDGF, transforming growth factor A1 (TGF-
A1), and TGF-2 promotes the migration of inflammatory cells such as leukocytes, 
neutrophils, and macrophages to the wound site. The inflammatory phase, characterized 
by the infiltration of neutrophils and macrophages, is crucial in supplying growth factor 





Figure 1.3. Cytokines released during the phases of acute wound healing are also 
present during cancer hallmark acquisition. (A) Tissue injury activates platelet recruitment 
to the site of injury, where a temporary fibrin clot stops blood vessel hemorrhage. Platelets 
release a heterogeneous mix of growth factors and cytokines (PDGF, TGF-b, IL-8, SDF-
1, CXCL4, bFGF, VEGF) that aid in the repair process. (B) The inflammatory phase 
begins with the influx of neutrophils followed by macrophages to the wound bed. 
Neutrophils begin the phagocytosis of debris in the wound and release chemokines 
(MCP-1 and CCL5) that recruit macrophages to the wound. With the reduction of 
neutrophils around days 2-4, macrophages become the dominant inflammatory cells in 
the wound. They not only protect the wound from foreign microorganisms, but they also 
release growth factors, chemokines, and cytokines (VEGF, bFGF, PDGF, TNF-a)	that aid 
in wound repair. (C) Around days 3-10, fibroblasts are recruited to the wound, where they 
contribute to the formation of a temporary ECM. (D) Several months to years after injury, 
cells leave the wound or undergo apoptosis, ECM is broken down by matrix 
metalloproteinases (MMPs) and metalloproteinase tissue inhibitors (TIMPs). Type III 
collage that was deposited during the proliferation phase is degraded and replaced by a 
more permanent Type I collagen. Growth factors and cytokines highlighted in the 4 
phases of wound healing are also actively involved in the hallmarks of cancer outlined by 
Hanahan and Weinberg (2011). Parallels in secreted factors of wound healing are 
observed in the following cancer hallmarks: tumor and repair promoting inflammation, 
sustaining proliferative signaling, and angiogenesis. The color scheme linking the 
association between the hallmarks of cancer and specific paracrine factors can be 
referenced using the figure legend. This figure was created using BioRender.com.   
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Neutrophils release a variety of inflammatory cytokines including TNF-a, IL-1b, and IL-6, 
IL-8, and MCP-1, which not only amplify the inflammatory response but also stimulate the 
release of VEGF and IL-8 to further enhance the repair response. Macrophages are 
described as key regulators in the response because of their roles in debris removal, 
promotion and conclusion of inflammation, and secretion of cytokines and growth factors 
for recruitment and activation of other cells involved in the repair process. The proliferative 
phase entails the replacement of temporary fibrin matrix with granulation tissue via 
fibroblast-driven ECM deposition. Growth factors produced by remaining inflammatory 
cells and migrating epidermal and dermal cells maintain cell proliferation and initiate cell 
migration to the wound bed. In response to the hypoxic wound environment, a robust 
angiogenic response is initiated and sustained by the production of VEGF, fibroblast 
growth factor 2 (FGF2), and PDGF by platelets and resident cells. In the final phase of 
remodeling, ECM components undergo multiple steps of degradation and synthesis to 
restore normal tissue architecture. The vascularization process initiated during the 
previous phase provides a favorable environment for continued epidermal and dermal 
cell migration and proliferation. This leads to wound re-epithelialization and restoration of 
epidermal integrity. Fibroblasts proliferate within the wound and synthesize ECM, which 
is initially composed of collagen III, fibronectin (FN1), fibrin, and hyaluronic acid. The initial 
matrix is then substituted with ECM mainly composed of collagen I. After wound 
contraction and matrix remodeling, fibroblasts undergo apoptosis and leave a relatively 
acellular scar that is comparable to the unwounded skin. The previous overview of the 
wound healing process strictly applies to acute wounds. Unlike acute wounds, chronic 
wounds exhibit prolonged or excessive inflammation, inability of dermal and epidermal 
cells to respond to reparative stimuli, or persistent infections (Fig. 1.4). Chronic wounds, 
including diabetic ulcers, pressure ulcers, and vascular ulcers, are all characterized by a 
chronically inflamed wound bed and failure to heal129. Although the differences between 
ECM composition of acute and chronic wounds is both minimal and controversial, studies 
have shown that chronic wounds are characterized by either prolonged or poor 
expression of fibronectin, chondroitin sulfate, and tenascin. This leads to impaired cell 
proliferation and migration129. Glycation, the attachment of sugars to matrix proteins, also 
contributes to matrix instability and disrupts interactions between collagen and its binding 
partners as observed in aging129. In chronic wounds, an excessive recruitment of 
inflammatory cells that produce various reactive oxygen species (ROS) results in the 
damage of ECM structural elements and cell membranes, leading to premature cell 
senescence129. Increased levels of matrix metalloproteinases (MMPs) also contributes to 
the degradation of ECM and inhibition of new ECM deposition130. In conjunction with pro-
inflammatory cytokines, ROS induces the production of enzymes that degrade and 
inactivate ECM components and growth factors necessary for normal cell function. 
Although chronic wounds exhibit an observed increase in growth factors compared to 
acute wounds, both their quality and bioavailability are compromised in chronic wounds. 
In addition to excessive inflammation chronic wounds also display impaired angiogenesis 
and neovascularization, which subsequently leads to insufficient oxygen and nutrient 
supply to cells within the wound bed.  Similar to a physiological wound, tumors activate 




Normal tissues are comprised of two components, the parenchyma and stroma. The 
stroma, a mixture of fixed tissue cells, inflammatory cells, blood vessels, matrix proteins, 
and proteoglycans, provides support to the parenchyma. Tumor composition is analogous 
to normal tissue, organized into the parenchyma (malignant cells) and stroma. Solid 
tumors such as carcinomas or sarcomas attain semblance to healing wounds by 
exploiting the host vascularized tissue stroma for survival, growth, and metastasis131-135. 
Troester et al. have shown that a wound response signature is activated in histologically 
normal tissue of breast cancer patients90. The overlapping phases of blood clotting, 
inflammation, extracellular matrix alterations, angiogenesis, and tissue remodeling are 
expressed in normal tissue adjacent to breast cancer and in tumors, further solidifying 
similarities between tumors and physiological wounds84, 136. The hallmarks of wound 
healing also parallel some of the hallmarks of cancer86. Out of the ten hallmarks of cancer, 
three of the hallmarks have close ties with the four phases of wound healing. Secretory 
factors observed in wound healing are also observed in cancer. Many of these factors are 
observed in multiple phases of wound healing and actively participate in multiple wound 
healing phases including TGF-b, VEGF, PDGF, basic fibroblast growth factor (bFGF), 
TNF-a, and IL-8 (Fig 1.3). One type of tumor that embodies the nature of malignant 
tumors and chronic wounds is the keloid scar. Keloid scars are characterized as benign 
human tumors without malignant potential that exhibit elevated matrix deposition and 
chronic inflammation137. Previously, keloids were characterized by an overabundance of 
disorganized type I and III collagen bundles138. Fibroblasts in keloids exhibit an altered 
phenotype of intrinsic or growth factor stimulated collagen, fibronectin, elastin, and 
proteoglycan accumulation139. Current studies have shown that new keloid lesions 
demonstrate elevated matrix protein expression of collagens (COL1A1, COL6A1, 
COL10A1, COL11A1, COL12A1), FN1, and fibrillin-2 (FBN2) compared to non-lesion 
tissue140, 141. Many of these same matrix components are observed to be elevated in triple 
negative breast cancer (TNBC) compared to matched non-diseased breast adipose 
tissue. TNBC is void of ER, PR, and HER2, characterizing it as a more aggressive breast 
cancer type. Previous studies have evaluated the matrix composition of TNBC compared 
to distal adipose tissue and observed elevated protein levels of COL6A1, COL11A1, 
COL12A1, FN1, and FBN2, with a minor increase in COL1A1140. Similar data was 
observed by others who profiled 13 TNBC samples compared to adjacent adipose 
tissue140. Another link between keloids and cancer progression is plasminogen activator 
inhibitor 1 (PAI-1). In in-vitro 3D culture, keloid fibroblasts show elevated collagen 
accumulation and altered fibrin degradation. PAI-1, a major inhibitor of plasminogen 
activators that are responsible for the conversion of plasminogen to plasmin, is thought 
to be linked with poor fibrin degradation observed in keloids99. For proper repair in the 
wound healing process, the temporary fibrin matrix must be degraded and replaced by 
fibroblast-synthesized collagen. In addition to organ fibrosis, PAI-1 also plays a role in 
tumor progression. Not only is it highly expressed in tumor biopsies, but it is also 
prognostic for disease progression and relapse in certain cancer types, one in particular 
being breast cancer142. PAI-1 can induce tumor vascularization, promote cell 
dissemination, and tumor metastasis142. Keloid-derived fibroblasts have been shown to 
exhibit elevated expression of transforming growth factor-b1 (TGFb-1) and transforming 
growth factor-b2 (TGF-b2)141, 143. TGFb has profound effects on PAI-1 upregulation in 
tissue and organ fibrosis. TGFb increases production of ECM molecules by cells and 
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slows down their removal by upregulating protease inhibitors (TIMP1 and PAI-1) and 
downregulating protease (MMP1 and uPA) expression139. Elevated TGFb-1 in 
hepatocellular carcinoma and breast, lung, and prostate cancer patients correlates with 
poor outcome144. In breast cancer, TGFb-1 exhibits a dual role as both tumor suppressive 
and oncogenic in nature. In early stages of breast cancer, TGFb-1 shows tumor 
suppressive effects by inhibiting epithelial cell cycle progression and promoting apoptosis. 
However, in the late stages of breast cancer, TGFb-1 is correlated with increased tumor 
progression, higher cell motility, cancer invasiveness, and metastasis145. Interestingly, 
with respect to patient age, the expression TGF-b, a growth factor responsible for the 
stimulating the synthesis of collagen and promoting wound healing, is markedly reduced 
in aged individuals compared to young146, 147. Similar to TNBC, keloid scarring has a 
higher prevalence in African Americans and in individuals between the age of 10 and 
30148, 149. Age and race appear to be common factors between keloid scarring and the 
more aggressive cancer subtypes such as TNBC. Data suggests that breast cancer in 
young women (<40 years old) have a poorer prognosis and higher mortality compared to 
breast cancers diagnosed in older women150, 151. Furthermore, young African American 
women (<40 years old) are more likely to be diagnosed at younger ages with a more 
Figure 1.4. Chronic wounds exhibit similarities to tumors. Acute wounds exhibit 
adequate angiogenesis that aids in fibroblast proliferation, re-epithelialization, and 
neutrophil infiltration. On the other hand, chronic wounds exhibit poor angiogenesis, 
elevated neutrophil infiltration, persistent bacterial infections, and decreased fibroblast 
proliferation. Higher infiltration of inflammatory cells leads to the excessive secretion of 
inflammatory markers, which leads to growth factor and ECM degradation. The chronic 
inflammation also prevents macrophage polarization from an inflammatory to anti-
inflammatory phenotype, which prevents resolution of the wound and maintains it in a 
non-healing state. Similar to chronic wounds, tumors also exhibit higher neutrophil and 
macrophage infiltrate, increased levels of pro-inflammatory cytokines, and ECM 
degradation as a result of inflammation. Unlike chronic wounds, tumors increase 
collagen synthesis. This figure was created using BioRender.com.  
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aggressive TNBC subtype152, 153. The commonalties between keloid scarring and TNBC 
may offer more insight into the role of age in tumorigenesis. To date, commonalities 
between age and TNBC has been established; however, the extent to which age impacts 
the ER-a+ subtype and TME has yet to be fully elucidated.  
 
1.4.2 ASCs: Their role in the physiological wound and TME 
 
Adipose tissue is a viable source of stromal/stem cells that exhibit both 
multipotency and immunomodulatory characteristics154-156. The regenerative capacity of 
ASCs is harnessed through their secretome157, 158. ASCs secrete a wide variety of growth 
factors, cytokines, adipokines, neurotrophic factors, adipokines, and angiogenic factors 
such as PDGF, FGF, VEGF, HGF, SDF-1, IL-6, IL-8, transforming growth factor alpha 
(TGF-a) and angiopoietin159-162. In vivo, ASCs reside in the stem cell niche, where they 
are surrounded by the ECM and other supporting cells163. The stem cell niche or more 
commonly referred to as the microenvironment, modulates the ability of ASCs to 
differentiate, proliferate, and migrate as they aid in the restoration of cellular age defects 
and tissue repair164. In response to injury, ASCs have been shown to shift the 
inflammatory phenotype of local immune cells to a more anti-inflammatory phenotype via 
soluble factors165. ASCs alter the inflammatory profiles of macrophages, T cells, B cells, 
and dendritic cells, which in turn furthers the proliferative and remodeling phases of the 
wound healing process166, 167. Many of these soluble factors described above are also 
associated with expressing and/or secreting multiple growth factors, cytokines, 
chemokines, and inflammatory markers that are linked to cancer development and 
progression168-176. ASCs promote the recovery of wound blood via the secretion of 
angiogenic factors. VEGF is the most important angiogenic growth factor because of its 
ability to promote endothelial progenitor cell mobilization, recruitment, and migration, 
which accelerates angiogenesis in the wound177. Heo et al. determined that TNF-a 
activated ASCs produce pro-inflammatory cytokines IL-6 and IL-8 aid in angiogenesis and 
epithelium regeneration in wound repair178, 179. Interestingly, high serum levels of both IL-
6 and IL-8 correlated with strong tumor invasion and poor prognosis in breast cancer180. 
In addition to VEGF, many angiogenic factors including PDGF and angiopoietin are 
secreted throughout several phases of the wound healing process181. Although beneficial 
during wound repair, both VEGF and PDGF aid in endothelial cell proliferation and 
vascularization of tumors181. TNF-a, a pro-inflammatory cytokine involved in systemic 
inflammation, is secreted by both ASCs and tumor cells. TNF-a  is upregulated in the 
inflammatory phase of wound healing. ASCs stimulate macrophages to secrete TNF-a, 
which further aids in activation, proliferation, apoptosis, and differentiation of other 
macrophages. TNF-a secreted by ASCs has been associated with the development of 
the tissue architecture necessary for tumor growth and metastasis182.  In addition, long 
term exposure of hormone receptor positive (HR+) breast cancer cells to TNF-a results in 
epithelial to mesenchymal transition (EMT) and a more aggressive phenotype182. In 
physiological wound healing, ASC-secreted IL-6 aids in macrophage recruitment and M1 
to M2 polarization164. Studies have exhibited that chronic inflammation associated with 
excessive IL-6 secretion facilitates tumor development182. MCP-1, another pro-
inflammatory cytokine produced by ASCs, promotes macrophage recruitment during 
wound healing. Similar to previously mentioned mediators, MCP-1 is also involved in 
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breast cancer tumor progression and metastasis182. LEP, an adipokine secreted by ASCs, 
stimulates angiogenesis, cell proliferation and differentiation, and migration of 
keratinocytes to enhance wound healing182. LEP also plays a crucial role in 
tumorigenesis. In HR+ breast cancer, LEP is correlated with higher recurrence rates and 
increased invasiveness76. LEP also increases TNF-a expression, ROS production, MCP-
1 expression, and endothelial cell proliferation and migration, all of which increase cancer 
cell growth and mobility182. As previously mentioned in terms of keloid formation, PAI-1 
contributes to proper wound healing through the breakdown of the fibrin clot. Studies have 
shown that ASC-secreted PAI-1 has been associated with tumor cell invasion and 
metastasis, as well as a poor prognostic indicator in breast and colon cancers182. 
Circulating levels and protein content of growth differentiation factor 11 (GDF11), a 
member of the TGF-b superfamily, is affected by pathological conditions and age183. It 
has a role in multiple phases of the wound healing process by increasing cell proliferation 
and migration, angiogenesis, and ECM production164. Studies on the effect of GDF11 and 
cancer progression are inconclusive. Some studies have shown that GDF11 induces 
tumor suppressive properties, while others indicate GDF11 promotes tumorigenesis183. 
Similar to GDF11, TGF-b1 is active in multiple steps of the wound healing process. TGF-
b1 plays the role of a paracrine mediator that activates fibroblasts, macrophages, and 
ASC secretions164. In breast cancer, TGF-b1 enhances progression of breast 
malignancies into more malignant phenotypes76. Increased expression of the chemokine 
SDF-1 by ASCs amplifies ASC migration to the wound site164. SDF-1 has also been noted 
as an important factor in the spread of breast cancer cells76. SDF-1 and its receptor, 
chemokine receptor type 4 (CXCR4), play an important role in HR+ breast cancer70. The 
expression of SDF-1-CXCR4 is associated with the EMT phenotype. Furthermore, 
crosstalk between ER-a, SDF-1, and CXCR4 contributes to hormone independence, 
making it increasingly difficult to treat with endocrine therapy70.  Although these specific 
soluble mediators have roles in both wound healing and tumorigenesis, the question 
arises concerning how their roles are altered by aging. Many of the regenerative qualities 
of ASCs including proliferation and differentiation capacity change with age. The ASC 
secretome has been harnessed as a viable treatment option for chronic non-healing 
wounds, however studies have yet to characterize the ASC secretome as a function of 
age184. Several of the aforementioned mediators including PDGF, VEGF, IL-6, TNF-a, 
SDF-1, TGF-b1, and LEP are affected by aging125(Table 1.4). Although little evidence 
suggests ASC-secreted PDGF is impacted by age, studies have shown that aging results  
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Table 1.4. Paracrine Factors Observed in Wound Healing and Tumorigenesis. Asterisk 
(*) indicates information was provided by a review article. 
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in the enhanced release of PDGF, TGF-b, and TGF-a from a-granules125.  Increased age 
also correlates with a decline in phagocytic activity of wound macrophages, leading to an 
accumulation in IL-6 and TNF-a125. In contrast, Pandey et al. revealed that aged ASCs 
exhibit lower expression of TNF-a relative to young ASCs. This suggests that the impact 
of aging on each cell type is distinct. Aging may have different effects on immune cells 
compared to tissue-derived cells such as ASCs. VEGF, an essential regulator of 
angiogenesis, has exhibited a decline in expression with aging125. In contrast, studies 
have shown that ASC-secreted VEGF levels is unaffected by age when active in bone 
healing185. Aging also results in a decrease in SDF-1 expression in wound healing, 
however there is no evidence suggesting that age affects ASC production of SDF-1125. 
Hypoxia plays a significant role in the physiologic wound healing process186. With aging, 
wound response to hypoxia diminishes, thus responsiveness to TGF-b1 also diminishes. 
In normal tissues, TGF-b1 increases the deposition of collagen by stimulating its 
synthesis and minimizing its degradation. In aged wound tissue, this ratio of synthesis to 
degradation is imbalanced125. The adipokine LEP not only promotes wound healing, but 
it also plays an oncogenic role in breast cancer187, 188. In a study by Pandey et al., LEP 
expression in aged ASCs was significantly lower compared to young ASCs189. With 
elevated levels in young ASCs and links to both wound healing and tumorigenesis, LEP 
could be a potential target underlying amplified tumor aggressiveness observed in young 
patients. Based on this investigation, paracrine factors have an extensive role in wound 
healing and tumorigenesis regardless of ASC involvement. We have knowledge that 
ASCs secrete the paracrine factors listed in Table 1.4, however, we can only speculate 
that ASCs releasee these factors in response to wound repair and tumorigenesis. ASCs 
are also recognized as playing a pivotal role in both wound healing and tumorigenesis. 
The extent to which age impacts the role of ASCs in both of these pathologies is not well 
understood. Studies on aging and cutaneous wound healing have highlighted changes in 
many of these secreted factors. While these factors are ASC associated, these changes 
have not yet been linked specifically to ASCs.   
 
1.4.3 Adipose-Derived Stem/Stromal Cells and ER-a+ Breast Cancer  
 
As previously described in section 1.1.2, the interaction between ASCs and the 
TME has adverse effects on breast cancer development and progression. Based on a 
review by Freese et al., numerous studies have been conducted to determine the role of 
ASCs in human breast cancer development, growth, progression, and metastasis169. The 
duality of ASCs as both regenerative and tumorigenic in nature makes their role in tumor 
development extremely complex. Many studies have suggested that the ability of ASCs 
to release pro-migratory factors may influence their role in cancer169, 190-193. Others have 
suggested ASCs play an important role in pathologic angiogenesis and formation of a 
blood supply for the growing tumor194. Crosstalk between ASCs and breast cancer cells 
diminishes the efficacy of hormonal therapy195. To date, the full impact of ASCs on the 
TME is yet to be established and may have confounding results due to differences in 
patient demographics that influence ASC function.  
Patient characteristics such as BMI can alter ASC function and the stimulatory 
effect on ER-a+ breast cancer. In non-cancerous tissue, obesity increases the expression 
of pro-inflammatory factors such as IL-6, IL-1, IL-12, PDGF, TNF-a, leukemia inhibitory 
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factor (LIF), and granulocyte-colony stimulating factor (GSF)196. Strong et al. discovered 
that LEP from obese ASCs (BMI greater than or equal to 30 kg/m2) promoted ER-a+ 
cancer growth and metastasis compared to those of a healthy BMI (18.5-24.9 kg/m2) 197, 
198.  LEP indirectly increases estrogen synthesis and ER-a activity by upregulating 
aromatase expression and activity in ER-a+ breast cancer cells199. ASCs exhibit an innate 
ability to drive ER-a+ breast cancer through aberrant paracrine signaling. In the absence 
of cell-cell contact, ASCs are able to increase the proliferation of MCF-7 cells70. This 
evidence suggests ASCs not only behave as protagonists in ER-a+ breast cancer, but 
also complicate treatment efforts. Their homing and immunomodulatory functions in 
observed in the wound healing and tissue regeneration process also appears to prime 
and transform sites into suitable environments for tumor growth199, 200.   As presented in 
this dissertation, ASCs may play a similar role in ER-a+ breast cancer and wound healing 
response. The body of evidence investigating ASCs from this perspective is still sparse; 
however, there is considerable amount of evidence focusing on BMSCs and their role in 
wound healing and cancer progression108. Many of the cytokines and growth factors that 
have been presented in section 1.4.2 as potential links between ASCs and the tumor 
wound have been previously cited in epithelial stem cells lines201. With this said, more 
short-term experiments focusing on the ASC secretome’s impact on wound healing and 
tumorigenesis need to be conducted to bridge this gap in knowledge. Rather than 
generalizing, studies need to focus on specific cancer types and specific ASC 
demographics. 
 
1.5 Overview of Research 
 
This dissertation is divided into three specific aims that focuses on the characterization of 
stromal age and breast cancer, specifically the impact of adipose-derived stem/stromal 
cells on regulation of endocrine signaling. These aims are designed to test the overall 
hypothesis that the young ASC secretome contributes to elevated estrogen signaling in 
ER-a+ breast cancer.  
 
Aim 1: Characterization of ER-a+ breast cancer tumors of young and aged patients. 
This aim is designed to determine differences in young and aged breast cancer tumors 
based on gene expression and resident cell population. Data acquired from The Cancer 
Genome Atlas (TCGA), GenEx Miner, Kaplan Meier plotter was used to investigate gene 
expression as a function of tumor age. TCGA and GenEx Miner was used to compare the 
gene expression of ER-a+ breast cancer tumors from aged and young patients. Kaplan 
Meier plotter was used to determine the impact of significant genes observed in the former 
platforms on the survival rate of ER-a+ breast cancer patients. xCell cell type enrichment 
analysis was implemented to characterize the cell infiltrate of young and aged tumors.  
 
Aim 2: Characterization of young ASCs. This aim was designed to evaluate young 
ASC phenotype. To determine the impact of ASCs on the stromal environment, we 
compared the proliferation, differentiation, matrix gene expression, and cytokine 
expression of young and aged ASCs. The proliferation and differentiation capacity of 
young and aged ASCs was assessed on tissue culture plastic. Matrix gene expression of 
 20 
young and aged ASCs was evaluated using qRT-PCR. The secretome of young and aged 
ASCs was compared using cytokine array analysis.   
 
Aim 3: Identify the role of the ASC secretome on ER-a+ breast cancer estrogen 
activity. This aim was designed to assess how the young ASC secretome affects ER-a+ 
breast cancer. The MCF-7 ER-a+ breast cancer cell line was exposed to conditioned 
media (CM) acquired from young and aged ASC donors and assessed for differences in 
proliferation and estrogen signaling. Proliferation of MCF-7 cells stimulated with young 
and aged CM was evaluated using Crystal Violet staining. Differences in estrogen 
signaling was compared in MCF-7 cells stimulated with young and aged CM using qRT-
































CHAPTER 2. THE CHARACTERIZATION OF YOUNG ASCs 
 
 
2.1 Introduction  
 
Aging is notably characterized as a progressive, generalized impairment of 
function, resulting in a poor response to environmental challenges and expanding risk of 
disease and death. Two of the many chronic diseases associated with aging are cancer 
and impaired wound healing. Wound healing occurs via a complex, coordinated series 
overlapping phases involving numerous cell types, tissues, cytokines, chemokines, 
growth factors, and proteolytic enzymes. The cellular activities including migration, 
proliferation, phagocytosis, and ECM synthesis are tightly regulated. The wound repair 
program follows the chronological order of hemostasis, inflammation, proliferation, and 
tissue remodeling to ensure optimal repair126. Tumors, an unconventional, non-healing 
wound, hijack the body’s wound repair program, creating an ideal environment for tumor 
growth and progression. Similar to a wound, tumors secrete factors that aid in the 
recruitment of multiple cell types including MSCs.  
 MSCs, derivatives of mesenchymal tissues including bone marrow and adipose 
tissue, display a propensity to migrate toward damaged tissues and organs where they 
then secrete cytokines to mediate wound healing98-100. The therapeutic effect of MSCs 
can be attributed to the release of these cytokines that promote new vessel formation, 
recruit endogenous cells, and direct cell differentiation, proliferation, and ECM formation 
during wound repair101-103.  Kilroy et al. characterized the cytokine profile of MSCs (mean 
age 37.8 yo +/- 10.6, BMI 25.4 kg/m2) showing that lipopolysaccharide (LPS)-stimulated 
MSCs not only release angiogenic (HGF, VEGF) and hematopoietic (IL-7, GM-CSF) 
cytokines, but also secrete a number of pro-inflammatory cytokines (IL-6, IL-8, IL-11, 
TNF-a)104.  The release of cytokines that both support and delay tissue recovery pose 
many questions concerning the role of MSCs in wound healing. Evidence has shown that 
MSCs not only aid in the healing of conventional wounds, but are also linked to the 
“wounds that never heal” observed in cancer. Age is a significant factor in both wound 
healing and cancer, yet few studies have focused on the characterization of MSCs on the 
basis of age. Previous studies have demonstrated that key demographic factors such as 
age and diseased states can alter stem cell biology202, 203. Modifications to the underlying 
biology of stem cells can result in an altered response to diseased states such as non-
healing wounds and cancer. In this study, we investigated the effect of age on ASC 
function. We compared the proliferation, differentiation, matrix deposition, and paracrine 
secretions of aged and young ASCs. Through an age-dependent characterization of 
ASCs, we intended to determine which ASC characteristics may impact the features 









2.2  Materials and Methods  
 
Cell Culture: 
Cell Source: Human adipose-derived stem/stromal cells (ASCs) were obtained from 
Obatala Sciences (New Orleans, LA). Young donors (24-34 years old, mean age 27.8 +/- 
4.1 SEM) and aged donors (60-70 years old, mean age 62+/- 7.8 SEM) matched 
according to corresponding body mass indices. All donors were female and Caucasian 
(Table S1).  
 
ASC Culture: Cultures of ASCs (3,000 cells/cm2) were maintained with Alpha-MEM with 
L-glutamine (Cat #: 12561-056, Gibco) supplemented with 10% fetal bovine serum (FBS, 
Cat #: 43602-500, JR Scientific) and 1% Antibiotic-Antimycotic (Anti-Anti, Cat #15240062, 
Gibco) until attained 80% confluence. The procedure implemented for ASC expansion 
was described previously by Bunnell et al 204. Cells were then seeded at 2,000 cells/cm2 
in 6-well plates, 3,000 cells/cm2 in 96-well plates, 3,000 cells/cm2, and 2,000 cells/cm2 in 
60 x 15 mm plates for qRT-PCR, immunostaining, proliferation, and differentiation assays. 
For coated ECM, aged and young ASCs were seeded at 3,000 cells/cm2 on laminin (Cat 
#: 354533, Corning) and fibronectin (Cat #: 354532, Corning) coated 25 cm2 flasks and 
maintained at 5% CO2 at 37°C until attaining 80% confluent and cells were collected for 
qRT-PCR. 
 
Adipogenic Differentiation: Cultured ASCs were detached, counted, and seeded in 6-well 
plates at 2,000 cells/cm2. Three days after plating, cells were induced using adipogenic 
differentiation medium (Cat #: OS-002-01, Obatala Sciences), changing medium every 3 
days for 14 days.  Cells were then washed 3x with Phosphate Buffer Solution (PBS, Cat 
#: 10010-023, Gibco) and fixed for 1 h with 10% formalin. Fixative was then removed and 
cells were washed 3x with PBS prior to staining with 0.5% Oil Red-O. After staining for 1 
h, wells were washed 3x with PBS and imaged using an inverted fluorescence 
microscope (Olympus IX-81, Olympus Corporation) and NIS Elements Microscope 
Imaging Software (Nikon).  
 
ASC Proliferation: Cultured ASCs were detached, counted, and seeded in 96-well plates 
at 3,000 cells/cm2 . Three days after plating, wells were maintained with culture medium 
(Alpha MEM with L-glutamine,10% FBS, and 1% Anti-Anti) or induced with osteogenic or 
adipogenic differentiation medium. Cell density at days 1, 3, 7, and 10 was assessed 
using the Cell Counting Kit-8 (CCK-8, Dojindo). Absorbance was measured using a cell 
imaging multimode reader (Cytation 3, BioTek) and Gen5 Microplate Reader and Imager 
Software (BioTek).  
 
Immunofluorescent Staining: Cultured ASCs were seeded in 96-well plates at 3,000 
cells/cm2 and maintained in culture medium for 24 h. Cells were then fixed with 10% 
formalin for 15 min, washed with PBS 3x, and permeabilized with 0.5% (v/v) Triton 100-
X for 10 min. After removing the detergent, cells were washed 3x with PBS and blocked 
with 0.1% (w/v) BSA in PBS for 1 h. With the removal of the blocking agent, cells were 
stained with 100 µL of Alexa Fluor 488 phalloidin for 30 min at room temperature (Cat 
#A12379, Invitrogen). This was proceeded by washing 3x with PBS and staining with 100 
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µL of DAPI diluted 1:300 in 0.1% (w/v) BSA for 10 min at room temperature (Cat#: 
157574, MP Biomedicals). Cells were then washed 3x with PBS and imaged using an 
inverted confocal fluorescence microscope (Leica SP8, Leica Microsystems) and Leica 
Application Suite X (LASX, Leica Microsystems).  
 
Quantitative Real-Time Polymerase Chain Reactions (qRT-PCR): ASCs were collected 
and total RNA was extracted with Quick RNA MicroPrep kit (Cat #: R1051, Zymo 
Research) as per manufacturer protocol. cDNA was synthesized using qScript cDNA 
SuperMix (Cat #: 101414-106, VWR), as per manufacture protocol with 1µg RNA per 
sample. Primer was obtained using Primer-BLAST software (NCBI). Primer sequences 
are presented in Table S2. Quantitative real-time PCR (qRT-PCR) was performed using 
the BioRad iCycler (BioRad, v4.006). Expression was computed using the comparative 
cycle threshold (Ct) method using the reference gene GAPDH. Normalization of young 
donor gene expression was to aged donor gene expression designated as 1.  
 
Cytokine array analysis: ASCs were cultured until attained 80% confluency in 10% Alpha-
MEM with L-glutamine (Cat #: 12561-056, Gibco) supplemented with 10% fetal bovine 
serum (FBS, Cat #: 43602-500, JR Scientific) and 1% Antibiotic-Antimycotic (Anti-Anti, 
Cat #15240062, Gibco). Cells were washed with sterile phosphate buffer saline (PBS, 
Cat #: 10010023, Gibco). ASCs were then cultured in phenol-free Dulbecco’s modified 
Eagle’s medium (Cat #:31053-028, Gibco), 5% charcoal stripped FBS (Cat #: 
SH3006803, GE Healthcare), 1% penicillin/streptomycin (P/S, Cat #: 15140-122, Gibco), 
1% MEMAA, 1% NEAA, 1% Glutamax (Cat #: 35050-061, Gibco), and 1% sodium 
pyruvate for 24 h. The conditioned media was collected, filtered, and stored at -20°C for 
cytokine array analysis. The cytokine array analysis procedures followed the 
manufacturer’s protocol (Cat #: ARY005B, R&D Systems, Minneapolis, MN).  
  
Biostatistics: All values are presented as means ± standard error (SEM). Statistical 
analyses among two groups were performed using the Student’s t-test. Statistical 
significance was set at p<0.05. Analysis was performed using Prism 8 (GraphPad 

















2.3  Results  
 
Adipose-derived stem/stromal cell differentiation, proliferation, and morphology is 





In order to determine the multi-lineage differentiation capacity of young and aged ASCs, 
ASCs were differentiated into adipogenic lineages using lineage specific induction factors. 
The number of aged ASCs capable of adipogenic differentiation parallel that of young 
ASCs (Fig 2.1C and 2.1D). Phalloidin staining of aged and young ASCs showed no visible 
difference in morphology (Fig 2.1A and 2.1B).  To test the proliferation of young and aged 
ASCs, ASCs were maintained in basal medium or differentiated into adipogenic lineages. 
Proliferation of ASCs in basal (Fig 2.1E) and adipogenic (Fig 2.1F) was measured at days 
1, 3, 7, and 10. Results revealed no significant difference in the proliferation of young and 





Figure 2.1. Young and aged ASCs exhibit comparable morphology, differentiation 
capacity. (A,B) Aged (A) and young (B) ASCs were maintained in stromal medium for 
7 days, stained with Alexa Fluor 488 Phalloidin, and counterstained with DAPI. (C,D) 
Adipogenic-differentiated aged (C) and young (D) ASCs were maintained 14 days in 
adipogenic differentiation medium. Oil Red-O was used to stain for lipid rich vacuoles. 
(E,F) Aged and young ASCs proliferation cultured in basal (E) and adipogenic (F) 
medium was assessed at days 1, 3, 7, and 10 using the Cell Counting Kit-8 (CCK-8). 
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Adipose-derived stem/stromal cell extracellular matrix gene expression is not altered by 



























To delineate differences between young and aged ASC extracellular matrix and 
intracellular signaling gene expression, ASCs were maintained in basal medium until 
attaining 80% confluency and collected for qRT-PCR analysis. There were no significant 
changes in ECM gene expression observed in young ASCs. Many ECM genes examined 
in qRT-PCR displayed high cycling and thus were no included the final analysis. Both 
COL4A2 (10.95 +/- 10.62 SEM) and LAMA3 (6.82 +/- 4.72 SEM) were elevated in young 












Figure 2.2. Young ASCs displayed similar expression of matrix 
compared to aged. Young and aged ASCs were cultured in basal 
medium and collected at 80% confluence for qRT-PCR analysis. 
Primers were chosen based on pooled young and aged ASC gene 
expression and TCGA data. N=3 biological replicates. Mean value 
represented by vertical bar.  
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Since there were no observed differences in ASC matrix expression between young and 
aged ASCs, we next sought to determine if paracrine factors were altered between young 
and aged ASCs. To compare the production of paracrine factors from aged and young 
ASCs, ASC cell supernates were collected, mixed with select antibodies, and incubated 
on the array. Chemiluminescence results revealed elevated levels of proteins MCP-1, 
CCL5, SDF-1, CD40, CXCL1, IFN-g, IL-8, IL-10, IL-16, IL-32a, and TNF-a in young ASC 
conditioned media (Fig 2.3). Many of these paracrine factors are associated specifically 
associated with the inflammatory phase of the wound healing process. Furthermore, 
many of these are also elevated in young tumors, suggesting young ASCs display similar 




Figure 2.3 Young tumors and ASCs exhibit a comparable inflammatory profile. (A) Young and 
aged ASC cytokine profile was assessed using cytokine array analysis. Young ASC cytokine 
expression is normalized to aged, N=2. (B) Several genes significantly (p<0.05) elevated in young 
ER-a+ tumors including CCL5, CD40L, IL-16, IL-32a, and SDF-1 paralleled expression exhibited 
in young ASCs. GSM-CSF and IL-4 expression was diminished in young ER-a+ tumors, however 



















Table 2.1 Comparison of young tumors and young ASC cytokine expression and their role 
in wound healing. 
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2.4  Discussion 
 
Aging is characterized by both intrinsic and extrinsic changes to the human anatomy, 
one in particular being modifications to the ECM. As a component of the 
microenvironment, the ECM not only alters MSC behavior, but also undergoes age-
associated changes that are linked to multiple pathologies including cancer205.  Although 
it has been extensively shown that the ECM undergoes compositional changes with age, 
results have been variable regarding the impact of age on MSC driven changes in ECM 
composition. Uncertainty exists regarding age-related changes in MSC collagen 
synthesis. Sun et al. found no difference in ECM total protein concentration synthesized 
by aged and young murine bone marrow derived stem cells (BMSCs)206. Similarly, our 
study shows no significant differences in ECM gene expression between aged and young 
ASCs. Furthermore, ASCs cultured on fibronectin and laminin proteins revealed no 
significant difference between aged and young. This suggests that age may not play a 
role in ASC ECM deposition. This study also revealed similarities between aged and 
young ASC proliferation and differentiation. Refuting evidence exists on the effect of age 
on ASC differentiation and proliferation. Kornicka et al. and Choudhery et al. both 
confirmed that ASC colony forming units (CFUs) and doubling time was affected by 
age207, 208.  In contrast, Dufrane et al. showed ASC expansion does not change based on 
donor age. Khan et al. observed a decline in osteogenic potential in aged donors, whereas 
Shi et al. reported no change with age43, 44. Pandey et al. also showed that ASCs from 
younger donors had a significantly elevated potential to differentiate toward adipogenic 
and osteogenic lineages189. These discrepancies suggest that a 2D platform may not 
provide clinically relevant insight into the role aging plays on ASC behavior. Traditionally, 
the hallmark of MSCs (and ASCs) was the ability to differentiate into various cell types for 
regenerative repair of damaged tissue54, 209, 210. However, many studies suggest that the 
treatment modality of MSCs occurs through the expression of cytokines and 
chemokines211. Numerous studies have focused on the age-related changes in ASC 
proliferation and differentiation; however, very few studies have delved into the effect of 
age on ASC paracrine function. Our study has shown an elevated level of cytokine and 
chemokine expression in young ASCs. Many of these factors including CXCL1, SDF-1, 
CCL5, IL-8, IL-10, and TNF-a are associated with various phases of the wound healing 
process. The ASC secretome has been harnessed as a cell-free treatment option for 
many conditions including wound healing. Although studies have shown that ASC 
paracrine activity has beneficial effects on non-healing wounds, evidence also indicates 
the secretome presents adverse effects on pathologies including cancer. Furthermore, 
no study to date has focused on the impact of ASC age on paracrine activity and its 
influence on disease progression. Since there are observed differences in aged and 
young ASC paracrine function, we will evaluate the extent to which those differences 











3.1 Introduction  
 
In the United States, approximately 1 in 8 women will develop invasive breast 
cancer212. The risk of breast cancer increases with age, a large percentage occurring in 
women 50 and older. Fewer than 5% of breast cancers occur in women under the age of 
40; however, breast cancer is the leading cause of cancer death amongst women 
between 20-39 yo213. Roughly 11 per 100,000 breast cancer patients between the ages 
of 15-39 years old have estrogen receptor-alpha (ER-a) positive tumors, making 
endocrine therapy the treatment of choice. Although initially successful, many patients 
develop resistance to treatment, resulting in the reappearance of cancer13. Young 
individuals that have luminal ER-a+ breast cancer have an observed increase in 
resistance to endocrine therapies such as tamoxifen214. Currently, there is neither specific 
focus evaluating mechanisms for resistance to therapy in young ER-a+ patient 
populations nor are current therapies designed to combat endocrine resistance evaluated 
in young ER-a+ breast cancer patients214, 215. Recently, attention has been directed to 
tumor microenvironment as an active participant in tumorigenesis and metastasis, as well 
as the progression toward hormone independence and endocrine therapy resistance37, 
216-218. Tumors are composed of a diverse population of stromal cells such as ASCs, 
endothelial cells, fibroblasts, adipocytes, and immune cells36, 219. The interaction between 
tumor cells and the microenvironment can be characterized as reciprocal. This interplay 
between normal cells, cancer cells, and the extracellular matrix contributes to the 
hallmarks of cancer including immunomodulation, angiogenesis, invasion and 
metastasis, and apoptotic resistance87. Similar to the wound healing process, the host 
response leads not only to the modification of secreted proteins from tumor cells and 
stroma, but also activates surrounding cells including ASCs220-224. ASCs, a multipotent 
cell population found in breast tissue, are an integral part of the tumor microenvironment. 
Although elicited for their multi-lineage differentiation and proactive role in tissue 
regeneration, ASCs are linked to breast cancer progression54, 207, 219, 225, 226. ASCs 
express and secrete multiple growth factors, cytokines, chemokines, and inflammatory 
biomarkers such as SDF-1 and IGF-1 that aid in cancer development and progression168, 
227, 228. These signaling molecules also enhance breast cancer progression and regulate 
resistance to endocrine therapies in ER-a+ breast cancer. Studies show that ASCs create 
a pro-inflammatory tumor microenvironment that promotes tumorigenic activity through 
the release of cytokines such as TNF-a, IL-6, and IL-8192. In addition, donor 
characteristics alter the ASC phenotype. Specifically, ASCs derived from obese donors 
are demonstrated as having elevated levels of LEP and contribute to endocrine resistance 
in ER-a+ breast cancer through LEP.  
The microenvironment or stem cell niche not only supports surrounding cell 
populations, but also provides diverse biophysical and biochemical cues for regulating 
cell behavior229. The ECM, a heterogeneous, non-cellular component of the 
microenvironment, guides the behavioral patterns of stem cells including self-renewal, 
quiescence, migration, differentiation, and apoptosis230-233. Aging of cells within this 
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specialized microenvironment or age-dependent modifications in the acellular 
components of the microenvironment can result in stem cell dysfunction234. As a 
component of the microenvironment, the ECM also undergoes age-related changes that 
compromises its mechanobiological role235. Studies have also shown that age-associated 
changes in ECM composition subsequently alters stem cell behavior236. Although the 
ECM alters the regenerative potential of stem cells, it is questionable as to whether or not 
it is permanent. When aged MSCs are seeded young MSC-derived ECM, the aged MSCs 
express greater pluripotency237. This further demonstrates the significance of the 
microenvironment and its potential as a medium to rejuvenate aged stem cells.   
Age-related changes in the ECM not only mediates cell proliferation, differentiation, 
inflammation, and apoptosis, but also impacts the recruitment and functional integration 
of ASCs236.  As a result, processes such as wound healing become less effective. Wound 
healing is a complex process involving the active participation of multiple cell types, 
biochemical mediators, cytokines, growth factors, and ECM components238, 239. The 
dynamics of a tumor parallel those of the wound healing process. Similar to a wound, 
tumors attract a diverse population of stromal cells including stem cells and immune 
cells219, 240. Although the stem cell response becomes damaging in light of tumor function 
and progression, it contrastingly exhibits regenerative properties for chronic wounds241-
244. Current research has yet to focus on the impact of stromal age on the development 
of endocrine resistance. In the present study, we assessed the effect of ASC age on the 
MCF-7 cell line in order to discover an underlying mechanism for the development of 
endocrine resistance.  
 
3.2  Materials and Methods  
 
Cell culture: MCF-7 human breast adenocarcinoma cell line was maintained in Dulbecco’s 
modified Eagle’s medium (DMEM, Cat #: 11965-092, Gibco, Waltham, MA) 
supplemented with 10% fetal bovine serum (FBS, Cat #: SH30087.03, GE Healthcare), 
1% Non-essential amino acids (NEAA, Cat #: 11140-050, Gibco), Minimal essential 
amino acids (MEMAA, Cat #: 11130-051, Gibco), sodium pyruvate (100 mM, Cat #: 
11360-070, Gibco), L-glutamine (Cat #:12561-056,, Gibco), Antibiotic-Antimycotic (Anti-
Anti, Cat #:15240062, Gibco), and insulin (4 mg/mL, Cat #: 12585-014, Gibco) at 37°C in 
humidified 5% CO2. MCF-7 cells were seeded at 3,000 cells/cm2 in T150 flasks until 
attained 80% confluence. Human adipose-derived stem/stromal cells (ASCs) were 
obtained from Obatala Sciences and Dr. Frank Lau. Young donors (24-34 years old) and 
aged donors (50-69 years old) were grouped by a specific age range (Table 1.5). Cultures 
of ASCs (3,000 cells/cm2) were maintained with Alpha-MEM with L-glutamine (Cat #: 
12561-056, Gibco) supplemented with 10% fetal bovine serum (FBS, Cat #: 43602-500, 
JR Scientific) and 1% Antibiotic-Antimycotic (Anti-Anti, Cat #15240062, Gibco) until 
attained 80% confluency. The procedure implemented for ASC expansion was described 
previously by Bunnell et al204. 
 
Conditioned media: ASCs were cultured until attaining 80% confluency in 10% Alpha-
MEM with L-glutamine (Cat #: 12561-056, Gibco) supplemented with 10% fetal bovine 
serum (FBS, Cat #: 43602-500, JR Scientific) and 1% Antibiotic-Antimycotic (Anti-Anti, 
Cat #15240062, Gibco). Cells were washed with sterile phosphate buffer saline (PBS, 
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Cat #: 10010023, Gibco). ASCs were then cultured in phenol-free Dulbecco’s modified 
Eagle’s medium (Cat #:31053-028, Gibco), 5% charcoal stripped FBS (Cat #: 
SH3006803, GE Healthcare), 1% penicillin/streptomycin (P/S, Cat #: 15140-122, Gibco), 
1% MEMAA, 1% NEAA, 1% Glutamax (Cat #: 35050-061, Gibco), and 1% sodium 
pyruvate for 24 h. The conditioned media was collected, filtered, and stored at -20°C. 
MCF-7 cells were treated with 0.25% Trypsin-EDTA (Cat #: 25200056, Gibco) and 
seeded at 50,000 cells/cm2 in 10 cm dishes. Cells were maintained in 10% DMEM at 
37°C in humidified 5% CO2 until 80% confluent. Once confluent, cells were maintained in 
conditioned media obtained from aged and young ASCs for 72 h or 15 min. Cells were 
then collected and stored at -80°C for RNA extraction and western blot analysis.  
 
Proliferation Assay: MCF-7 cells were seeded at 50 cells/cm2 in 96-well plates. Cells were 
maintained in 10% DMEM at 37°C in humidified 5% CO2 and treated with conditioned 
media after 24 h. At days 0, 1, 5, and 7, cells were fixed with 95% methanol for 10 min. 
They were washed 3x with PBS prior to crystal violet staining. Cells were stained with 3% 
crystal violet solution and incubated at room temperature for 1 h. The wells were washed 
with water then allowed to dry prior to imaging. After dissolving in 33% acetic acid, 
absorption was determined at 595 nm using the Cytation 3.  
 
Differentiation Assays: ASCs were cultured until attained 80% confluency in 10% Alpha-
MEM with L-glutamine supplemented with 10% FBS and 1% Anti-Anti. Adipogenic 
differentiation medium (AdipoQual, Obatala Sciences, New Orleans, LA) was introduced 
for 3 days and alternated with MCF-7 conditioned medium for 3 days for an 11-day period. 
Cells were then collected and stored at -80°C for RNA extraction and qRT-PCR analysis.  
 
Quantitative Real Time PCR (qRT-PCR): RNA was extracted from cell pellets using 
QIAshredders (Cat #: 79656, Qiagen) and RNeasy Mini Kit (Cat #: 74106, Qiagen) as per 
manufacturer instructions. Complementary DNA (cDNA) was synthesized using qScript 
cDNA SuperMix (Cat #: 101414-106, VWR), and 1μg total RNA. Quantitative PCR was 
performed using the BioRad iCycler (BioRad, v4.006) and Quanta SYBR green (VWR, 
Radnor, PA) as per manufacture’s protocol. Expression was computed using the ΔΔ(Ct) 
method using the reference gene GAPDH (ASCs) and b-Actin (MCF-7s). Primer 
sequences are presented in Table S2. Normalization was to aged ASC gene expression 
designated as 1. 
 
Western blot analysis: MCF-7 cells were seeded at 50,000 cells/cm2 in 10 cm dishes. 
Cells were maintained in 10% DMEM at 37°C in humidified 5% CO2 until 80% confluent. 
At 80% confluency, 10% DMEM was removed and either 5% charcoal stripped media, 
5% charcoal stripped media with estrogen (Cat #: E2758-1G, Sigma Aldrich, St. Louis, 
MO, 1 µg/mL), or conditioned media from aged and young ASC donors was added to the 
dishes. After 15 min at 37°C in humidified 5% CO2, the media was removed, cells were 
washed, and cells were collected on ice and stored at -80°C.   Cell pellets were lysed 100 
μL of mammalian protein extraction reagent (M-PER, Cat #:78501, ThermoFisher 
Scientific, Waltham, MA) supplemented with 1x Halt protease and phosphatase inhibitor 
(Cat #:78444, ThermoFisher Scientific). BCA protein assays were run on the cell extracts 
and 1µg of total protein was mixed with a master mix (Cat #:SM-W004, ProteinSimple, 
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San Jose, CA) to give a final concentration of 0.2 mg/mL total protein. Samples were 
heated at 95 °C for 5 min. Samples, blocking solution, primary antibodies (ER-α, Santa 
Cruz # sc-543, 1:50; actin, Novus Biologicals # NB600-501H, 1:500; phospho-ER-α 
serine 167, Cell Signaling #64508 1:25; phospho-ER-α serine 118, Cell Signaling #2511 
1:25, phospho-ERK1/2, Cell Signaling #4307 1:25; total ERK, Cell Signaling #4695 1:50; 
phospho-AKT, Cell Signaling #4060 1:25; total AKT, Cell Signaling #4691 1:50), 
horseradish peroxidase-conjugated secondary antibodies (Cat#:DM-002, ProteinSimple), 
chemiluminescent substrate (Cat #:DM-002, ProteinSImple), and separation and stacking 
matrices (Cat #:SM-W004, ProteinSimple) were loaded into designated wells in a 384-
well plate according to the manufacturer’s instructions. After plate loading, fully automated 
electrophoresis and immunodetection took place in the WES capillary system 
(ProteinSimple). Proteins were separated by molecular weight at 375V for 25 min, and 
primary and secondary antibodies incubated for 30 minutes. Chemiluminescence was 
captured by a charge-coupled device camera, and the digital image analyzed using 
Compass software (ProteinSimple). The amount of each protein was calculated based on 
peak area. A virtual image is shown based on peaks from the electropherogram.  
 
xCell Cell Type Enrichment Analysis: Immune and stromal cell infiltrate of young and aged 
ER-a+ was analyzed using the xCell webtool. Ductal and lobular neoplasms were selected 
from the case set of the TCGA-BRCA project (phs000178.v11.p8) derived from the NIH 
Genomic Data Commons (GDC) Data Portal245. Based on the clinical information 
provided with the TCGA-BRCA project, tumors were grouped into young (<45 years old) 
and aged (>65 years old) categories. These selected cases were matched with pre-
calculated TCGA data provided by the xCell webtool.  
 
Breast cancer data sources and analysis: Invasive breast carcinoma data set 
(IlluminaHiSeq) from The Cancer Genome Atlas (TCGA) research network was evaluated 
for differences in gene expression between young and aged patients based on ER status. 
Data base for Annotation, Visualization and Integrated Discovery v6.8 (DAVID v6.8) was 
used to identify enriched functional-related gene groups found of interest in the TCGA 
dataset246.The Breast Cancer Gene-Expression Miner v4.4 (bc-GenExMiner v4.4) was 
used to perform an age-dependent comparison in gene expression of significant genes 
from the TCGA data247. Original data analyzed in bc-GenExMiner was acquired from the 
NCI GDC Data Portal248. The population selected was based solely on age, not receptor 
status. The Kaplan-Meier Plotter was used to assess the effect of targeted genes on the 
survival of ER-a+ breast cancer patients249. Cell enrichment analysis of young and aged 
ER-a+ breast tumors was performed using the xCell webtool250.  
 
Biostatistics: All values are presented as means ± standard error (SEM). Statistical 
analyses among two groups were performed using the Student’s t-test. Statistical 
significance was set at p<0.05. Analysis was performed using Prism 8 (GraphPad 






3.3  Results  
 
Tumor micro-environment composition is altered in young ER-a+ breast cancer compared 
to age. 
 
According to the NCI Surveillance, Epidemiology, and End Results Program (SEER), HR+ 
breast cancer patients ages 15-39 years old have a lower survival rate (87.7%) compared 
to ages 65-74 years old (95.6%) and 75+ years old (94.2%). To better identify 
distinguishing features and underlying mechanisms for lower survival rates observed in 
young ER-a+ patients, previously aligned and published data derived from The Cancer 
Genome Atlas (TCGA) IlluminaHiSeq invasive breast cancer was analyzed for differences 
between aged and young patient populations251-253. Tumor samples were separated 
based on ER-a+ receptor status and age (young individuals <40 years old and aged 
















Results demonstrated that key pathways enriched in young ER-a+ breast cancer samples 
were those associated with the extracellular matrix (COL6A6, ITGA1, ITGA10, ITGA2, 
ITGA4, LAMA1, LAMA2, LAMB3, LAMC1, LAMC2, LAMC3), focal adhesions, cytokine-
cytokine interactions (CCL19, CCL21, CCR4, CCR6, CXCL5, CXCL9, CD27, IL12B, 
IL20), PI3K/AKT, and NF-kB (TNFRSF13B, TNFAIP3, TNFSF11) (Fig 3.1). Specifically, 
tumors from young individuals had higher levels of matrix genes and these genes 
correlated with poor patient survival.  
In depth analysis of genes enriched in young (<40 years old) ER-a+ breast cancer 
compared to aged ER-a+ (>65 years old) demonstrated that in addition to matrix, 
increased cytokines associated with a pro-inflammatory phenotype (CCL5, IL12-B, IL-20, 
IL-11, IL-19) and growth factors (FGF-1, PDGFB, SDF-1, IGF-1) were also detected. The 
Figure 3.1. Tumor microenvironment is differentially regulated in young and aged ER-
a+ breast cancer patients. DAVID functional annotation tool was used to determine 
enriched pathways of elevated genes in the TCGA data set. Results revealed 
significant p values (p<0.05) for matrix, focal adhesion, cytokine, PI3K/AKT, and NF-




increase in pro-inflammatory cytokines and growth factors suggests the tumors may be 
eliciting support from surrounding cell types, specifically stem cells220, 254. Comparison of 
breast tumor cell infiltration revealed significant differences (p<0.05) in CD8+ T-cells, T-
helper 2 (Th2) cell, and M2 macrophages between young and aged ER-a+ breast tumors 
(Fig 3.2A). Young tumors exhibited higher xCell scores for CD8+ T-cells (0.02± 0.003) 
and Th2 cells (0.04 ± 0.004), but a lower score for anti-inflammatory M2 macrophages 
(0.01 ±0.0008). In contrast to immune cell infiltration, both MSC and adipocyte xCell  





With an increase in specific stromal components in both the TCGA and enrichment data, 
we next sought to determine the role of these specific components in patient survival. 
Although selected genes exhibited increased expression in young in the TCGA data, they 









Figure 3.2. Immune cell infiltrate differs between young and aged ER-a+ breast cancer 
patients. (A) xCell cell type enrichment analysis of young (<45 years old) and aged (>65 
years old) ER-a+ breast cancer patients revealed significant p values (p<0.05) for M2 
macrophages, CD8+ T cells, and Th2 cells. Both CD8+ T cells and Th2 cells are enriched 
in young tumors while M2 macrophages exhibit a lower quantity compared to aged.  (B) 







Breast tumors exhibit age-dependent differences in specific stromal components. 
 
The Breast Cancer Gene-Expression Miner (bc-GenExMiner) was used to evaluate the 
age-dependent expression of genes linked to paracrine signaling. Targeted genes in age 
groups <40 years old, 40-70 years old, and >70 years old were compared to determine 
Significant differences in gene expression between 0-40 years old and 70-90 years old 
was observed in CXCL1 and COL5A2. On the other hand, TCGA data comparing young 
and aged HR+ tumors revealed significant differences in multiple genes (Table 3.1). Many 
of these observed paracrine factors are pro-inflammatory, suggesting an inflammatory 
response may play a role in the young patient tumor microenvironment.    
 
Figure 3.3. High expression of targeted genes exhibits no impact on 
patient survival. Kaplan Meier plots of elevated genes in young ER+ breast 
tumors were used to evaluate the effect of expression on patient survival. 
All plots displayed did not indicate a correlation between high expression 




























Table 3.1 Comparison of bc-Genex Miner and TCGA Paracrine Factor Expression in 
Young Tumors.   
bc-GenExMiner p-values represent the comparison between 0-40 and 70-90 years old. 
TCGA p-values represent the comparison between <45 years old and >65 years old.    
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Since age affects ASC paracrine signaling, we then assessed the effect of the ASC 
secretome on ER-a+ breast cancer. To evaluate the effect of the secretome on 
proliferation, MCF-7 cancer cells were treated with CM obtained from aged and young 
ASCs. Crystal violet staining revealed increased proliferation of MCF-7 cells treated with 
CM from young ASCs (684.5 +/-69.78 SEM) compared to those treated with aged CM 
(480.4 +/-158.2 SEM) at day 7(Fig 3.4). The proliferation of MCF-7 cells treated with 
young, CM showed significant change from day 1 to day 7 (p<0.05) whereas those treated 
with aged, conditioned medium showed no significance in proliferation. To determine if 
the increased proliferation was mediated through endocrine signals, ER-a  response 
genes were evaluated via qRT-PCR. Results show that the ER-a regulated genes PGR 
and SDF-1 were increased by 1 (+/- 0.44 SEM) and 1.25 (+/- 0.35 SEM) respectively in 
MCF-7 cells treated with young  
ASC CM when compared to those treated with aged CM (Fig 3.5). Protein expression of 
upstream ER-a regulators and their ER-a phosphorylation sites was evaluated to further 
determine the role of the ASC secretome on MCF-7 endocrine signaling.  After stimulation 
with conditioned medium for 15 min, MCF-7 cells were collected for western blot analysis. 
Results revealed an increase at p-ER S167 in MCF-7 cells exposed to young CM, 
suggesting that ASC signaling is mediated through the estrogen receptor. To confirm 
these results, MCF-7 cells were treated with tamoxifen for 4h prior to stimulation with 
aged or young CM. Cell were collected after 24h and ER-a response genes were 
evaluated with qRT-PCR. While elevated in the presence of young CM, ER-a shows loss 
of signal in the presence of tamoxifen. These results suggest that ER-a plays a key role 
in stem cell signaling. To further validate the effect of stem cell signaling on ER-a activity, 
MCF-7 cells were treated with aged and young CM followed by treatment with adipogenic 
differentiation media for 11 days. qRT-PCR results revealed no difference in gene 
Figure 3.4. Young ASC secretome enhances MCF-7 proliferation. MCF-7 cells were 
treated with CM from young or aged ASCs and proliferation via crystal violet was 
evaluated at days 0, 1, 5, and 7. MCF-7 cells treated with young CM showed greater 
proliferation through absorption (A) and visual staining (B). 
* 
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expression of ER-a, PGR, and SDF-1 between aged and young. The loss of stemness 
and commitment to an adipogenic phenotype results in comparable ER-a expression in 




Figure 3.5. Young ASC secretome enhances estrogen signaling in MCF-7 cell lines. (A) MCF-7 
cells were cultured with young and aged ASC CM and collected for qRT-PCR. Both PGR and 
SDF-1 expression were significantly different (p<0.05) from aged expression. (B) MCF-7s were 
cultured with young and aged ASC CM and evaluated for total and phosphorylated AKT, ERK, 
and ER protein expression using Western blot analysis. Results show an increase at p-ER-
S167 in MCF-7s stimulated with young CM. (C) MCF-7 cells were treated with tamoxifen 4 h 
before being treated with either young or aged ASC CM. MCF-7 cells were collected after 24 h 
for qRT-PCR to evaluate ER regulated gene expression. Results confirm that ASC signaling is 
mediated by ER. (D) Differences in gene expression between young and aged is lost with 
adipogenic differentiation.  
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3.4  Discussion 
 
The microenvironment plays a pivotal role in directing cell behavior. Strong evidence 
supporting the significance of the microenvironment on cell behavior is demonstrated in 
heterochronic parabiosis studies. The breast cancer microenvironment is defined as a 
combination of cells within the tumor and its stroma, the ECM, and surrounding signaling 
molecules255. In recent years, an overwhelming amount of evidence supports that the 
tumor microenvironment, and more specifically components of the ECM, contribute to 
breast cancer progression and metastasis205, 256-262. Furthermore, studies have shown 
that the tumor microenvironment actively participates in the progression toward hormone 
independence and endocrine therapy resistance69, 216, 263. Age-related physical and 
compositional changes in the ECM is linked to tumor progression264. Although it is well-
documented that specific extracellular matrix gene profiles are associated with the 
prognosis and treatment of breast cancer, little evidence is known about how local cellular 
function, specifically the ASC secretome, contributes to endocrine resistance in young 
ER-a+ breast cancer patients264-268. The extent to which ASCs, a resident of the breast 
cancer microenvironment, affect breast cancer progression and response to treatment 
has yet to be fully elucidated. Previous studies indicate that ASC age has no bearing on 
ECM dynamics. Although active in ECM production, ASCs also have both a paracrine 
and immunomodulatory function.  In regenerative medicine, ASCs are no longer solely 
used for cell restoration. Their secretion of trophic factors has been harnessed as a viable 
approach for tissue regeneration. Although beneficial in terms of regenerative medicine, 
the paracrine actions of ASCs may enable tumor formation, growth, and maintenance.  
The expression of paracrine factors between young and aged BC tumors is strikingly 
different. Chemokines including CXCL1 and IL-8 both exhibited elevated expression in 
young ASCs in the cytokine array analysis. Increased CXCL1 protein expression is 
associated with increased tumor growth and pulmonary metastasis in MDA-MB-231 
breast cancer cells269. Furthermore, increased expression of CXCL1 RNA is associated 
with a decreased survival of patients with ER-a+ breast cancer270. IL-8, a pro-inflammatory 
chemokine that promotes neutrophil chemotaxis and degranulation, is typically 
upregulated in breast cancer and associated with poor prognosis271. The monocyte 
attracting chemokine CCL5 was also upregulated in young ASCs. Studies have shown 
that an overexpression of CCL5 in breast tumor cells results in increased invasiveness272. 
SDF-1, a chemokine naturally secreted by MSCs, is an important mediator of MSC 
chemotaxis and primary breast tumorigenesis68, 217. SDF-1, another cytokine elevated in 
young ASCs, has been shown to promote hormone independent growth in the hormone 
dependent MCF-7 line70. As an ER-a-regulated gene, SDF-1 is suggested to play a role 
in the progression of breast carcinoma cells273, 274. The amount of SDF-1 secretion by 
MSCs has shown variance based on microenvironmental factors, one of which could be 
age275, 276. SDF-1 signaling also contributes to chemotherapy resistance in cancer cells 
by modulating survival pathways such as AKT, NOTCH, and the BCL-2 family277, 278. 
Although tumor expression of specific cytokines, chemokines, and growth factors is 
correlated with poor patient survival, Kaplan Meier plots of TNF-a,  IL-16, IL-32, SDF-1, 
IGF-1, and CD27 do not reflect those same findings. Rather than examining singular 
genes, further analysis these genes and patient survival must be performed using gene 




Breast cancer is composed of a large cellular array: ASCs, adipocytes, fibroblasts, 
immune cells, and endothelial cells. The analysis of cell infiltrate in young and aged breast 
tumors has revealed significant differences between several immune cell populations 
including CD8+ T cells, M2 macrophages, and Th2 (Fig 3.6A and B). Previous studies 
have shown that CD8+ T cells, T-helper 1 (Th1) cells, M1 macrophages, and natural killer 
(NK) cells exhibit anti-tumor activities, whereas T-regulatory (Treg) cells and M2 
macrophages exhibit immune-inhibitory, pro-tumor activities279. Interestingly, M2 
Figure 3.6. Young ER-a+ breast tumor stroma exhibits significant differences in specific 
matrix components and immune cell types. (A) Young tumor stroma (<45 years old) 
revealed significantly higher levels of matrix components (fibronectin, integrin a and b, 
collagen III, collagen V, collagen VI, collagen VII, and laminins A, B, and C) and immune 
cell types (CD8+ T cells and Th2 cells) (p<0.05). (B) Aged tumor stroma (>65 years old) 
revealed a significantly higher M2 macrophage infiltrate (p<0.05) compared to young 
stroma. The young and aged tumor stroma exhibit comparable numbers for MSC and 
adipocyte infiltrate; however, young MSCs may exhibit a greater potency and stimulate 
a rapid estrogen signaling pathway via cytokine and growth factor secretions. This 
contributes to the increased ER-a signaling and increased proliferation observed in 
MCF-7 cells stimulated with young CM compared to those stimulated with aged CM. 
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macrophage infiltrate was significantly lower in young compared to aged tumors, and 
CD8+ T cells were significantly higher in young compared to aged tumors. Although Jin 
and Hu determined that CD8+ T cells are associated with disease-free survival in young 
breast cancer patients compared to aged, Ali et al showed that CD8+ T cells infiltrate 
predicts a more favorable outcome for ER- tumors than ER+ tumors280, 281. Based on the 
literature, there is still no conclusive evidence identifying significant biological differences 
and T-cell immune infiltration between young and aged ER+ breast cancer patients281. 
With discrepancies in immune cell infiltration as prognostic indicators, other stromal cells 
have been exploited as possible prognostic indicators for breast cancer. Although MSC 
infiltration in young and aged breast tumors were not significantly different, MSCs may 
influence age-dependent tumorigenesis in an alternative manner. Rather than directly 
infiltrating the tumor, it is suggested that MSCs prime the site for tumor cell growth via 
secretion of high levels of multiple growth factors, cytokines, and chemokines70. Younger 
patients may have MSCs that secrete higher volumes of pro-tumorigenic factors 
compared to aged, thus resulting in poor prognoses in young patients with specific 
subtypes including ER+ and TNBC. Patient age correlates with stem cell potency, 
inflammatory secretion, and differentiation capacity189, 207, 282. Studies on BMSCs noted 
that aged stem cells had a lack of receptors for cytokines and chemokines, including 
TNFR and loss of these receptors resulted in an inability to respond to immune signals 
from the surrounding environment283. Together this suggests that young stroma, 
specifically young ASCs, may be more reactive to cytokine signals in a tumor environment 
than aged stroma. Prior studies evaluating differences in young and aged ASCs 
demonstrate that young ASCs have increased levels of pro-inflammatory signaling (MCP-
1, IL-8, TNF-a) and adipogenic markers (PPARg) compared to aged ASCs284.  TNF-a is 
critical for ER-a+ breast cancer progression and released in response to estrogen 
stimulation284, 285. 
TNF-a is not only secreted by tumor cells, but is also produced by ASCs. TNF-a 
production by tumors has been linked with poor prognosis and loss of hormone 
responsiveness286. The interaction of TNF-a with TNFRs activates downstream targets 
including the pro-inflammatory transcription factor NF-kB. NF-kB consists of a family of 
transcription factors that contribute to inflammation, immunity, cell proliferation, 
differentiation, and survival. The interaction of NF-kB with ER-a is one of the mechanisms 
of estrogen signaling. ER-a acts through several different mechanisms. Direct genomic 
signaling is the traditional mechanism of estrogen signaling. The binding of the dimerized 
estrogen receptors leads to nuclear translocation and binding to estrogen response 
elements (EREs) sequences of target genes12. Estrogen can also induce rapid, non-
genomic signaling in which estrogen induces gene transcription and protein synthesis by 
alternative mechanisms. The activation of signaling cascades including the PKC pathway, 
RAS/RAF/MAPK pathway, PI3K/AKT pathway, and the cAMP/PKA pathway leads to 
subsequent activation and binding of a variety of transcription factors (i.e. C/EBPb, NF-
kB, STAT) to alternative DNA response elements12, 16-21. Adding to the complexity of 
estrogen signaling, estrogen receptors can also be activated in the absence of estrogens 
or other receptor agonists22. Ligand-independent estrogen receptor activation occurs via 
the phosphorylation of specific residues (i.e. serine or tyrosine) in the receptors 
themselves or by coregulators such as PKA, MAPK, PKC, inflammatory cytokines (i.e. IL-
2), and peptide growth factors (i.e. IGF-1, TGFb, EGF). Evidence has demonstrated that 
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the crosstalk between ER-a  and many of the aforementioned growth factors and 
inflammation-associated transcription factors including NF-kB results in acquired 
endocrine resistance287-295. 
Although ER-a has been shown to repress the transcriptional activity of NF-kB, 
reports have also exhibited the existence of positive crosstalk between ER-a and NF-
kB296-298. Studies have shown that constitutive activation of NF-kB in breast tumors is 
correlated with more aggressive ER-a+ tumors, the development of resistance to 
endocrine therapy, and progression to estrogen-independent growth299-303. It has also 
been reported that cytokines and chemokines released in the cancer-induced 
inflammatory environment activates NF-kB-associated pathways that desensitize SERM 
response304. Long term antihormonal therapy alters ER-a driven regulation of metabolism 
and inflammation which also results in the constitutive activation of NF-kB305-307. The 
constitutive activation of the canonical NF-kB pathway is not only triggered by ER-a, but 
also by TNF-a. TNF-a activation of NF-kB results in the transcription of cytokines 
including IL-8, IL-1b, and a positive feedback loop resulting in NF-kB dependent TNF-a 
production33. Both IL-8 and TNF-a exhibit increased expression in both young ASCs and 
tumor samples from young breast cancer patients. As previously mentioned in section 
1.4, NF-kB expression is elevated in older donors; however, commonly associated 
molecules including IL-1a, TNF-a, iNOS, IL-8, and IkB were significantly downregulated 
in older donors189. Furthermore, older donors exhibited elevated concentrations of NF-kB 
in the cytosol whereas younger donors displayed an accumulation of NF-kB in the 
nucleus. An accumulation of NF-kB subunits in the cytosol suggests decreased 
transcriptional activity, thus verifies the decreased pro-inflammatory cytokines and 
molecules observed in older donors.  
A link between ER-a and NF-kB possibly lies at the Serine 167 (Ser-167) residue 
on ER-a. NF-kB is normally sequestered in the cytoplasm of most cells and bound to the 
inhibitory proteins IkB. IkB kinase a (IKKa) phosphorylates IkB proteins, leading to the 
degradation and subsequent activation of NF-kB gene expression.  A study by Bennett 
et al. has shown that increased IKKa levels correlate with reduced cancer-specific 
survival and reduced recurrence-free survival in ER+ breast cancer308. In addition to IKKa, 
the non-canonical kinase IKKe has been identified as an important mediator of 
inflammatory and oncogenic signaling. IKKe as a breast cancer oncogene has been 
amplified and overexpressed in over 30% of breast carcinomas and breast cancer cell 
lines309. It has been shown that IKKe phosphorylates Ser-167 of ER-a, and activation of 
ER-a contributes to tamoxifen resistance in breast cancer. Western blot analysis results 
from this study indicate increased expression of p-SER-167 in MCF-7 cells stimulated 
with young ASC conditioned media. Ser-167 is located within the hormone-independent 
transcriptional activation function 1 (AF-1) region, suggesting the phosphorylation of this 
site behaves independently of estrogen-ER-a interactions310, 311. Future studies should 
further explore the role of the NF-kB pathway on ASC-mediated estrogen-independent 
signaling in young ER-a+ breast cancer patients.  
In addition to TNF-a, CD40 ligand (CD40L) may contribute to the onset of 
endocrine resistance. CD40L, an activator the noncanonical NF-kB pathway, showed 
elevated expression in young patient tumors. CD40L binding to its receptor CD40 results 
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in the transcription of SDF-1, a cytokine that is elevated in both young patient tumors and 
young ASCs. In addition to TNF-a, CD40L expression may have an underlying role in NF-
kB activation and subsequent endocrine resistance in young ER-a+ breast cancer 
patients.  
Through this study, we have observed that the ASC secretome enhances estrogen 
independent signaling in the ER-a+ MCF-7 cell line. There is also limited evidence that 
the aged ASC secretome impacted MCF-7 cells in a manner comparable to the young 































































































































Table S2. qRT-PCR oligonucleotide primers. 
 46 
APPENDIX B. PERMISSION REQUESTS  
 
Figure 1.1. was reproduced from Musgrove, E., Sutherland, R. Biological determinants 
of endocrine resistance in breast cancer. Nat Rev Cancer 9, 631–643 (2009). 
https://doi.org/10.1038/nrc2713. Below is a copy of permission obtained from 
http://www.copyright.com. 
 
SPRINGER NATURE LICENSE 
TERMS AND CONDITIONS 




This Agreement between Katie Hamel ("You") and Springer Nature ("Springer Nature") 
consists of your license details and the terms and conditions provided by Springer Nature and 
Copyright Clearance Center. 
License Number 4997161303134 
License date Jan 27, 2021 
Licensed Content Publisher Springer Nature 
Licensed Content Publication Nature Reviews Cancer 
Licensed Content Title Biological determinants of endocrine resistance in breast cancer 
Licensed Content Author Elizabeth A. Musgrove et al 
Licensed Content Date Dec 31, 1969 
Type of Use Thesis/Dissertation 
Requestor type academic/university or research institute 
Format print and electronic 
Portion figures/tables/illustrations 
Number of figures/tables/illustrations 1 
Will you be translating? no 
Circulation/distribution 1 - 29 
Author of this Springer Nature content no 
Title Ph.D. Candidate  
Institution name Louisiana State University  
Expected presentation date Mar 2021  
Portions Figure 1  
Requestor Location 
Katie Hamel 





MADISONVILLE, LA 70447 
United States 
Attn: Katie Hamel 
Total 0.00 USD  
Terms and Conditions  
Springer Nature Customer Service Centre GmbH 
Terms and Conditions 
This agreement sets out the terms and conditions of the licence (the Licence) between you 
and Springer Nature Customer Service Centre GmbH (the Licensor). By clicking 'accept' 
and completing the transaction for the material (Licensed Material), you also confirm your 
acceptance of these terms and conditions. 
1. Grant of License 
 
 
1. The Licensor grants you a personal, non-exclusive, non-transferable, world-
wide licence to reproduce the Licensed Material for the purpose specified in 
your order only. Licences are granted for the specific use requested in the order 
and for no other use, subject to the conditions below. 
2. The Licensor warrants that it has, to the best of its knowledge, the rights to 
license reuse of the Licensed Material. However, you should ensure that the 
material you are requesting is original to the Licensor and does not carry the 
copyright of another entity (as credited in the published version). 
3. If the credit line on any part of the material you have requested indicates that it 
was reprinted or adapted with permission from another source, then you should 
also seek permission from that source to reuse the material. 
2. Scope of Licence 
 
 
1. You may only use the Licensed Content in the manner and to the extent 
permitted by these Ts&Cs and any applicable laws. 
2. A separate licence may be required for any additional use of the Licensed 
Material, e.g. where a licence has been purchased for print only use, separate 
permission must be obtained for electronic re-use. Similarly, a licence is only 
valid in the language selected and does not apply for editions in other languages 
unless additional translation rights have been granted separately in the licence. 
Any content owned by third parties are expressly excluded from the licence. 
3. Similarly, rights for additional components such as custom editions and 
derivatives require additional permission and may be subject to an additional 




om for these rights. 
4. Where permission has been granted free of charge for material in print, 
permission may also be granted for any electronic version of that work, 
provided that the material is incidental to your work as a whole and that the 
electronic version is essentially equivalent to, or substitutes for, the print 
version. 
5. An alternative scope of licence may apply to signatories of the STM 



































Figure 1.4. was reproduced from Meirelles, L., Fontes, A. M., Covas, D. T., & Caplan, A. 
I. (2009). Mechanisms involved in the therapeutic properties of mesenchymal stem 
cells. Cytokine & growth factor reviews, 20(5-6), 419 -
427. https://doi.org/10.1016/j.cytogfr.2009.10.002. Below is a copy of permission 
































Title	 Ph.D.	Candidate	  
 50 
Institution	name	 Louisiana	State	University	  
Expected	presentation	date	 Mar	2021	  











Total	 0.00	USD	   
































1. AlFakeeh, A. and C. Brezden-Masley, Overcoming endocrine resistance in 
hormone receptor-positive breast cancer. Curr Oncol, 2018. 25(Suppl 1): p. S18-
s27. 
2. Howlader, N., et al., US incidence of breast cancer subtypes defined by joint 
hormone receptor and HER2 status. J Natl Cancer Inst, 2014. 106(5). 
3. Parise, C.A., et al., Breast cancer subtypes as defined by the estrogen receptor 
(ER), progesterone receptor (PR), and the human epidermal growth factor 
receptor 2 (HER2) among women with invasive breast cancer in California, 1999-
2004. Breast J, 2009. 15(6): p. 593-602. 
4. Vuong, D., et al., Molecular classification of breast cancer. Virchows Arch, 2014. 
465(1): p. 1-14. 
5. McGuire, W.L., Hormone receptors: their role in predicting prognosis and 
response to endocrine therapy. Semin Oncol, 1978. 5(4): p. 428-33. 
6. Lapidus, R.G., S.J. Nass, and N.E. Davidson, The loss of estrogen and 
progesterone receptor gene expression in human breast cancer. J Mammary 
Gland Biol Neoplasia, 1998. 3(1): p. 85-94. 
7. Paterni, I., et al., Estrogen receptors alpha (ERα) and beta (ERβ): subtype-
selective ligands and clinical potential. Steroids, 2014. 90: p. 13-29. 
8. Abdallah, B.M., et al., Inhibition of osteoblast differentiation but not adipocyte 
differentiation of mesenchymal stem cells by sera obtained from aged females. 
Bone, 2006. 39(1): p. 181-8. 
9. Ali, S. and R.C. Coombes, Estrogen receptor alpha in human breast cancer: 
occurrence and significance. J Mammary Gland Biol Neoplasia, 2000. 5(3): p. 
271-81. 
10. Marino, M., P. Galluzzo, and P. Ascenzi, Estrogen signaling multiple pathways to 
impact gene transcription. Curr Genomics, 2006. 7(8): p. 497-508. 
 52 
11. O'Malley, B.W., A life-long search for the molecular pathways of steroid hormone 
action. Mol Endocrinol, 2005. 19(6): p. 1402-11. 
12. Klinge, C.M., Estrogen receptor interaction with estrogen response elements. 
Nucleic Acids Res, 2001. 29(14): p. 2905-19. 
13. Osborne, C.K. and R. Schiff, Mechanisms of endocrine resistance in breast 
cancer. Annu Rev Med, 2011. 62: p. 233-47. 
14. Prossnitz, E.R. and M. Barton, The G-protein-coupled estrogen receptor GPER 
in health and disease. Nat Rev Endocrinol, 2011. 7(12): p. 715-26. 
15. Filardo, E.J., et al., Estrogen-induced activation of Erk-1 and Erk-2 requires the G 
protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the 
epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol, 
2000. 14(10): p. 1649-60. 
16. Marino, M., V. Pallottini, and A. Trentalance, Estrogens cause rapid activation of 
IP3-PKC-alpha signal transduction pathway in HEPG2 cells. Biochem Biophys 
Res Commun, 1998. 245(1): p. 254-8. 
17. Dos Santos, E.G., et al., Rapid nongenomic E2 effects on p42/p44 MAPK, 
activator protein-1, and cAMP response element binding protein in rat white 
adipocytes. Endocrinology, 2002. 143(3): p. 930-40. 
18. Watters, J.J., et al., Rapid membrane effects of steroids in neuroblastoma cells: 
effects of estrogen on mitogen activated protein kinase signalling cascade and c-
fos immediate early gene transcription. Endocrinology, 1997. 138(9): p. 4030-3. 
19. Marino, M., F. Acconcia, and A. Trentalance, Biphasic estradiol-induced AKT 
phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. Mol Biol 
Cell, 2003. 14(6): p. 2583-91. 
20. Gu, Q. and R.L. Moss, 17 beta-Estradiol potentiates kainate-induced currents via 
activation of the cAMP cascade. J Neurosci, 1996. 16(11): p. 3620-9. 
21. Picotto, G., V. Massheimer, and R. Boland, Acute stimulation of intestinal cell 
calcium influx induced by 17 beta-estradiol via the cAMP messenger system. Mol 
Cell Endocrinol, 1996. 119(2): p. 129-34. 
 53 
22. Bennesch, M.A. and D. Picard, Minireview: Tipping the balance: ligand-
independent activation of steroid receptors. Mol Endocrinol, 2015. 29(3): p. 349-
63. 
23. Maggi, A., Liganded and unliganded activation of estrogen receptor and hormone 
replacement therapies. Biochim Biophys Acta, 2011. 1812(8): p. 1054-60. 
24. Vrtačnik, P., et al., The many faces of estrogen signaling. Biochem Med 
(Zagreb), 2014. 24(3): p. 329-42. 
25. Nilsson, S., et al., Mechanisms of estrogen action. Physiol Rev, 2001. 81(4): p. 
1535-65. 
26. Daniel, A.R., C.R. Hagan, and C.A. Lange, Progesterone receptor action: 
defining a role in breast cancer. Expert Rev Endocrinol Metab, 2011. 6(3): p. 
359-369. 
27. Cui, X., et al., Insulin-like growth factor-I inhibits progesterone receptor 
expression in breast cancer cells via the phosphatidylinositol 3-
kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a 
potential indicator of growth factor activity in breast cancer. Mol Endocrinol, 2003. 
17(4): p. 575-88. 
28. Kim, H.-J., et al., Progesterone Receptor Loss Correlates with Human Epidermal 
Growth Factor Receptor 2 Overexpression in Estrogen Receptor–Positive Breast 
Cancer. Clinical Cancer Research, 2006. 12(3): p. 1013s-1018s. 
29. Orlando, L., et al., Molecularly targeted endocrine therapies for breast cancer. 
Cancer Treat Rev, 2010. 36 Suppl 3: p. S67-71. 
30. Fedele, P., et al., Targeted agents to reverse resistance to endocrine therapy in 
metastatic breast cancer: where are we now and where are we going? Crit Rev 
Oncol Hematol, 2012. 84(2): p. 243-51. 
31. Hayes, E., R.I. Nicholson, and S. Hiscox, Acquired endocrine resistance in breast 
cancer: implications for tumour metastasis. Front Biosci (Landmark Ed), 2011. 
16: p. 838-48. 
 54 
32. Davies, C., et al., Relevance of breast cancer hormone receptors and other 
factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of 
randomised trials. Lancet, 2011. 378(9793): p. 771-84. 
33. Fan, P. and V.C. Jordan, New insights into acquired endocrine resistance of 
breast cancer. Cancer Drug Resistance, 2019. 2(2): p. 198-209. 
34. Rani, A., et al., Endocrine Resistance in Hormone Receptor Positive Breast 
Cancer–From Mechanism to Therapy. Frontiers in Endocrinology, 2019. 10(245). 
35. Paget, S., The distribution of secondary growths in cancer of the breast. 1889. 
Cancer Metastasis Rev, 1989. 8(2): p. 98-101. 
36. Dvorak, H.F., Tumors: Wounds That Do Not Heal-A Historical Perspective with a 
Focus on the Fundamental Roles of Increased Vascular Permeability and 
Clotting. Semin Thromb Hemost, 2019. 45(6): p. 576-592. 
37. Hanahan, D. and L.M. Coussens, Accessories to the crime: functions of cells 
recruited to the tumor microenvironment. Cancer Cell, 2012. 21(3): p. 309-22. 
38. Bertolini, F., et al., Adipose tissue cells, lipotransfer and cancer: a challenge for 
scientists, oncologists and surgeons. Biochim Biophys Acta, 2012. 1826(1): p. 
209-14. 
39. Sadlonova, A., et al., Human breast fibroblasts inhibit growth of the MCF10AT 
xenograft model of proliferative breast disease. Am J Pathol, 2007. 170(3): p. 
1064-76. 
40. Erler, J.T. and V.M. Weaver, Three-dimensional context regulation of metastasis. 
Clin Exp Metastasis, 2009. 26(1): p. 35-49. 
41. Whiteside, T.L., The tumor microenvironment and its role in promoting tumor 
growth. Oncogene, 2008. 27(45): p. 5904-12. 
42. Balkwill, F. and L.M. Coussens, Cancer: an inflammatory link. Nature, 2004. 
431(7007): p. 405-6. 
 55 
43. Greten, F.R., et al., IKKbeta links inflammation and tumorigenesis in a mouse 
model of colitis-associated cancer. Cell, 2004. 118(3): p. 285-96. 
44. Pikarsky, E., et al., NF-kappaB functions as a tumour promoter in inflammation-
associated cancer. Nature, 2004. 431(7007): p. 461-6. 
45. Fantuzzi, G., Adipose tissue, adipokines, and inflammation. J Allergy Clin 
Immunol, 2005. 115(5): p. 911-9; quiz 920. 
46. Strong, A.L., et al., Obesity associated alterations in the biology of adipose stem 
cells mediate enhanced tumorigenesis by estrogen dependent pathways. Breast 
cancer research : BCR, 2013. 15(5): p. R102-R102. 
47. Strong, A.L., et al., Obesity Enhances the Conversion of Adipose-Derived 
Stromal/Stem Cells into Carcinoma-Associated Fibroblast Leading to Cancer Cell 
Proliferation and Progression to an Invasive Phenotype. Stem Cells Int, 2017. 
2017: p. 9216502. 
48. De Wever, O., et al., Stromal myofibroblasts are drivers of invasive cancer 
growth. Int J Cancer, 2008. 123(10): p. 2229-38. 
49. Angelucci, C., et al., Epithelial-stromal interactions in human breast cancer: 
effects on adhesion, plasma membrane fluidity and migration speed and 
directness. PLoS One, 2012. 7(12): p. e50804. 
50. Zhao, M., et al., Mesenchymal stem cells in mammary adipose tissue stimulate 
progression of breast cancer resembling the basal-type. Cancer Biol Ther, 2012. 
13(9): p. 782-92. 
51. Kucerova, L., et al., Adipose tissue-derived human mesenchymal stem cells 
mediated prodrug cancer gene therapy. Cancer Res, 2007. 67(13): p. 6304-13. 
52. Zuk, P.A., et al., Human adipose tissue is a source of multipotent stem cells. Mol 
Biol Cell, 2002. 13(12): p. 4279-95. 
53. Hauner, H., P. Schmid, and E.F. Pfeiffer, Glucocorticoids and insulin promote the 
differentiation of human adipocyte precursor cells into fat cells. J Clin Endocrinol 
Metab, 1987. 64(4): p. 832-5. 
 56 
54. Pittenger, M.F., et al., Multilineage potential of adult human mesenchymal stem 
cells. Science, 1999. 284(5411): p. 143-7. 
55. Indrawattana, N., et al., Growth factor combination for chondrogenic induction 
from human mesenchymal stem cell. Biochem Biophys Res Commun, 2004. 
320(3): p. 914-9. 
56. Kocan, B., et al., Trophic Activity and Phenotype of Adipose Tissue-Derived 
Mesenchymal Stem Cells as a Background of Their Regenerative Potential. 
Stem Cells Int, 2017. 2017: p. 1653254. 
57. Salgado, A.J., et al., Adipose tissue derived stem cells secretome: soluble factors 
and their roles in regenerative medicine. Curr Stem Cell Res Ther, 2010. 5(2): p. 
103-10. 
58. Meirelles Lda, S., et al., Mechanisms involved in the therapeutic properties of 
mesenchymal stem cells. Cytokine Growth Factor Rev, 2009. 20(5-6): p. 419-27. 
59. Hsiao, S.T., et al., Comparative analysis of paracrine factor expression in human 
adult mesenchymal stem cells derived from bone marrow, adipose, and dermal 
tissue. Stem Cells Dev, 2012. 21(12): p. 2189-203. 
60. Borsig, L., et al., Inflammatory chemokines and metastasis--tracing the 
accessory. Oncogene, 2014. 33(25): p. 3217-24. 
61. Tögel, F., et al., Vasculotropic, paracrine actions of infused mesenchymal stem 
cells are important to the recovery from acute kidney injury. Am J Physiol Renal 
Physiol, 2007. 292(5): p. F1626-35. 
62. Banas, A., et al., IFATS collection: in vivo therapeutic potential of human adipose 
tissue mesenchymal stem cells after transplantation into mice with liver injury. 
Stem Cells, 2008. 26(10): p. 2705-12. 
63. Ben-Baruch, A., The Tumor-Promoting Flow of Cells Into, Within and Out of the 
Tumor Site: Regulation by the Inflammatory Axis of TNFα and Chemokines. 
Cancer Microenviron, 2012. 5(2): p. 151-64. 
64. Huang, B., et al., CCL2/CCR2 pathway mediates recruitment of myeloid 
suppressor cells to cancers. Cancer Lett, 2007. 252(1): p. 86-92. 
 57 
65. Gales, D., et al., The Chemokine CXCL8 in Carcinogenesis and Drug Response. 
ISRN Oncol, 2013. 2013: p. 859154. 
66. Aldinucci, D. and A. Colombatti, The inflammatory chemokine CCL5 and cancer 
progression. Mediators Inflamm, 2014. 2014: p. 292376. 
67. Soria, G. and A. Ben-Baruch, The inflammatory chemokines CCL2 and CCL5 in 
breast cancer. Cancer Lett, 2008. 267(2): p. 271-85. 
68. Stich, S., et al., Gene expression profiling of human mesenchymal stem cells 
chemotactically induced with CXCL12. Cell Tissue Res, 2009. 336(2): p. 225-36. 
69. Orimo, A., et al., Stromal fibroblasts present in invasive human breast 
carcinomas promote tumor growth and angiogenesis through elevated SDF-
1/CXCL12 secretion. Cell, 2005. 121(3): p. 335-48. 
70. Rhodes, L.V., et al., Adult human mesenchymal stem cells enhance breast 
tumorigenesis and promote hormone independence. Breast Cancer Res Treat, 
2010. 121(2): p. 293-300. 
71. Engelhardt, E., et al., Chemokines IL-8, GROalpha, MCP-1, IP-10, and Mig are 
sequentially and differentially expressed during phase-specific infiltration of 
leukocyte subsets in human wound healing. Am J Pathol, 1998. 153(6): p. 1849-
60. 
72. Kobayashi, Y., The role of chemokines in neutrophil biology. Front Biosci, 2008. 
13: p. 2400-7. 
73. Broughton, G., 2nd, J.E. Janis, and C.E. Attinger, The basic science of wound 
healing. Plast Reconstr Surg, 2006. 117(7 Suppl): p. 12s-34s. 
74. Abkowitz, J.L., et al., Mobilization of hematopoietic stem cells during 
homeostasis and after cytokine exposure. Blood, 2003. 102(4): p. 1249-53. 
75. Gao, Z., et al., Mesenchymal stem cells: a potential targeted-delivery vehicle for 
anti-cancer drug, loaded nanoparticles. Nanomedicine, 2013. 9(2): p. 174-84. 
 58 
76. Schweizer, R., et al., The role of adipose-derived stem cells in breast cancer 
progression and metastasis. Stem Cells Int, 2015. 2015: p. 120949. 
77. Prantl, L., et al., Adipose tissue-derived stem cells promote prostate tumor 
growth. Prostate, 2010. 70(15): p. 1709-15. 
78. Karnoub, A.E., et al., Mesenchymal stem cells within tumour stroma promote 
breast cancer metastasis. Nature, 2007. 449(7162): p. 557-63. 
79. Park, Y.M., S.H. Yoo, and S.H. Kim, Adipose-derived stem cells induced EMT-
like changes in H358 lung cancer cells. Anticancer Res, 2013. 33(10): p. 4421-
30. 
80. Anders, C.K., et al., Breast carcinomas arising at a young age: unique biology or 
a surrogate for aggressive intrinsic subtypes? J Clin Oncol, 2011. 29(1): p. e18-
20. 
81. Anders, C.K., et al., Young age at diagnosis correlates with worse prognosis and 
defines a subset of breast cancers with shared patterns of gene expression. J 
Clin Oncol, 2008. 26(20): p. 3324-30. 
82. Palmer, M.L., L. Herrera, and N.J. Petrelli, Colorectal adenocarcinoma in patients 
less than 40 years of age. Dis Colon Rectum, 1991. 34(4): p. 343-6. 
83. Marble, K., S. Banerjee, and L. Greenwald, Colorectal carcinoma in young 
patients. J Surg Oncol, 1992. 51(3): p. 179-82. 
84. Schäfer, M. and S. Werner, Cancer as an overhealing wound: an old hypothesis 
revisited. Nat Rev Mol Cell Biol, 2008. 9(8): p. 628-38. 
85. Dvorak, H.F., Tumors: wounds that do not heal-redux. Cancer Immunol Res, 
2015. 3(1): p. 1-11. 
86. MacCarthy-Morrogh, L. and P. Martin, The hallmarks of cancer are also the 
hallmarks of wound healing. Sci Signal, 2020. 13(648). 
87. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 
2011. 144(5): p. 646-74. 
 59 
88. Chang, H.Y., et al., Gene expression signature of fibroblast serum response 
predicts human cancer progression: similarities between tumors and wounds. 
PLoS Biol, 2004. 2(2): p. E7. 
89. Iyer, V.R., et al., The transcriptional program in the response of human 
fibroblasts to serum. Science, 1999. 283(5398): p. 83-7. 
90. Troester, M.A., et al., Activation of host wound responses in breast cancer 
microenvironment. Clin Cancer Res, 2009. 15(22): p. 7020-8. 
91. Riss, J., et al., Cancers as Wounds that Do Not Heal: Differences and Similarities 
between Renal Regeneration/Repair and Renal Cell Carcinoma. Cancer 
Research, 2006. 66(14): p. 7216-7224. 
92. Groessl, M., et al., Proteome profiling of breast cancer biopsies reveals a wound 
healing signature of cancer-associated fibroblasts. J Proteome Res, 2014. 
13(11): p. 4773-82. 
93. Balkwill, F. and A. Mantovani, Inflammation and cancer: back to Virchow? 
Lancet, 2001. 357(9255): p. 539-45. 
94. Antonio, N., et al., The wound inflammatory response exacerbates growth of pre-
neoplastic cells and progression to cancer. Embo j, 2015. 34(17): p. 2219-36. 
95. Eming, S.A., T. Krieg, and J.M. Davidson, Inflammation in wound repair: 
molecular and cellular mechanisms. J Invest Dermatol, 2007. 127(3): p. 514-25. 
96. de Visser, K.E., A. Eichten, and L.M. Coussens, Paradoxical roles of the immune 
system during cancer development. Nat Rev Cancer, 2006. 6(1): p. 24-37. 
97. Balkwill, F., K.A. Charles, and A. Mantovani, Smoldering and polarized 
inflammation in the initiation and promotion of malignant disease. Cancer Cell, 
2005. 7(3): p. 211-7. 
98. Chamberlain, G., et al., Concise review: mesenchymal stem cells: their 
phenotype, differentiation capacity, immunological features, and potential for 
homing. Stem Cells, 2007. 25(11): p. 2739-49. 
 60 
99. Jackson, W.M., L.J. Nesti, and R.S. Tuan, Concise review: clinical translation of 
wound healing therapies based on mesenchymal stem cells. Stem Cells Transl 
Med, 2012. 1(1): p. 44-50. 
100. Fitzsimmons, R.E.B., et al., Mesenchymal Stromal/Stem Cells in Regenerative 
Medicine and Tissue Engineering. Stem Cells Int, 2018. 2018: p. 8031718. 
101. Garg, R.K., et al., Capillary Force Seeding of Hydrogels for Adipose-Derived 
Stem Cell Delivery in Wounds. STEM CELLS Translational Medicine, 2014. 3(9): 
p. 1079-1089. 
102. Badiavas, E.V. and V. Falanga, Treatment of chronic wounds with bone marrow-
derived cells. Arch Dermatol, 2003. 139(4): p. 510-6. 
103. Rustad, K.C., et al., Enhancement of mesenchymal stem cell angiogenic capacity 
and stemness by a biomimetic hydrogel scaffold. Biomaterials, 2012. 33(1): p. 
80-90. 
104. Kilroy, G.E., et al., Cytokine profile of human adipose-derived stem cells: 
expression of angiogenic, hematopoietic, and pro-inflammatory factors. J Cell 
Physiol, 2007. 212(3): p. 702-9. 
105. Aggarwal, S. and M.F. Pittenger, Human mesenchymal stem cells modulate 
allogeneic immune cell responses. Blood, 2005. 105(4): p. 1815-22. 
106. Tsyb, A.F., et al., In vitro inhibitory effect of mesenchymal stem cells on 
zymosan-induced production of reactive oxygen species. Bull Exp Biol Med, 
2008. 146(1): p. 158-64. 
107. Corcione, A., et al., Human mesenchymal stem cells modulate B-cell functions. 
Blood, 2006. 107(1): p. 367-72. 
108. Li, P., et al., Mesenchymal stem cells: From regeneration to cancer. Pharmacol 
Ther, 2019. 200: p. 42-54. 
109. Ren, G., et al., Tumor resident mesenchymal stromal cells endow naïve stromal 
cells with tumor-promoting properties. Oncogene, 2014. 33(30): p. 4016-20. 
 61 
110. Ren, G., et al., CCR2-dependent recruitment of macrophages by tumor-educated 
mesenchymal stromal cells promotes tumor development and is mimicked by 
TNFα. Cell Stem Cell, 2012. 11(6): p. 812-24. 
111. Escobar, P., et al., IL-1β produced by aggressive breast cancer cells is one of the 
factors that dictate their interactions with mesenchymal stem cells through 
chemokine production. Oncotarget, 2015. 6(30): p. 29034-47. 
112. Yu, P.F., et al., TNFα-activated mesenchymal stromal cells promote breast 
cancer metastasis by recruiting CXCR2(+) neutrophils. Oncogene, 2017. 36(4): 
p. 482-490. 
113. Hu, M.S., et al., Mesenchymal Stromal Cells and Cutaneous Wound Healing: A 
Comprehensive Review of the Background, Role, and Therapeutic Potential. 
Stem Cells Int, 2018. 2018: p. 6901983. 
114. Huang, Y., et al., p53 regulates mesenchymal stem cell-mediated tumor 
suppression in a tumor microenvironment through immune modulation. 
Oncogene, 2014. 33(29): p. 3830-8. 
115. Gazdic, M., et al., Mesenchymal Stem Cells Promote Metastasis of Lung Cancer 
Cells by Downregulating Systemic Antitumor Immune Response. Stem Cells Int, 
2017. 2017: p. 6294717. 
116. Han, Z., et al., Immunosuppressive effect of bone marrow-derived mesenchymal 
stem cells in inflammatory microenvironment favours the growth of B16 
melanoma cells. J Cell Mol Med, 2011. 15(11): p. 2343-52. 
117. Ling, W., et al., Mesenchymal stem cells use IDO to regulate immunity in tumor 
microenvironment. Cancer Res, 2014. 74(5): p. 1576-87. 
118. Liotta, F., et al., Mesenchymal stem cells are enriched in head neck squamous 
cell carcinoma, correlates with tumour size and inhibit T-cell proliferation. Br J 
Cancer, 2015. 112(4): p. 745-54. 
119. Barcellos-de-Souza, P., et al., Tumor microenvironment: bone marrow-
mesenchymal stem cells as key players. Biochim Biophys Acta, 2013. 1836(2): p. 
321-35. 
 62 
120. Cuiffo, B.G. and A.E. Karnoub, Mesenchymal stem cells in tumor development: 
emerging roles and concepts. Cell Adh Migr, 2012. 6(3): p. 220-30. 
121. Ridge, S.M., F.J. Sullivan, and S.A. Glynn, Mesenchymal stem cells: key players 
in cancer progression. Molecular Cancer, 2017. 16(1): p. 31. 
122. Ashcroft, G.S., S.J. Mills, and J.J. Ashworth, Ageing and wound healing. 
Biogerontology, 2002. 3(6): p. 337-45. 
123. Gouin, J.P., L. Hantsoo, and J.K. Kiecolt-Glaser, Immune dysregulation and 
chronic stress among older adults: a review. Neuroimmunomodulation, 2008. 
15(4-6): p. 251-9. 
124. Miller, K.D., et al., Cancer statistics for adolescents and young adults, 2020. CA: 
A Cancer Journal for Clinicians, 2020. 70(6): p. 443-459. 
125. Sgonc, R. and J. Gruber, Age-Related Aspects of Cutaneous Wound Healing: A 
Mini-Review. Gerontology, 2013. 59(2): p. 159-164. 
126. Shaw, T.J. and P. Martin, Wound repair at a glance. Journal of Cell Science, 
2009. 122(18): p. 3209-3213. 
127. Ridiandries, A., J.T.M. Tan, and C.A. Bursill, The Role of Chemokines in Wound 
Healing. Int J Mol Sci, 2018. 19(10). 
128. Leibovich, S.J. and R. Ross, The role of the macrophage in wound repair. A 
study with hydrocortisone and antimacrophage serum. Am J Pathol, 1975. 78(1): 
p. 71-100. 
129. Demidova-Rice, T.N., M.R. Hamblin, and I.M. Herman, Acute and impaired 
wound healing: pathophysiology and current methods for drug delivery, part 1: 
normal and chronic wounds: biology, causes, and approaches to care. Adv Skin 
Wound Care, 2012. 25(7): p. 304-14. 
130. Turner, N.J. and S.F. Badylak, The Use of Biologic Scaffolds in the Treatment of 
Chronic Nonhealing Wounds. Adv Wound Care (New Rochelle), 2015. 4(8): p. 
490-500. 
 63 
131. Brown, L.F., et al., Fibrinogen influx and accumulation of cross-linked fibrin in 
healing wounds and in tumor stroma. Am J Pathol, 1988. 130(3): p. 455-65. 
132. Dvorak, H.F., Vascular permeability factor/vascular endothelial growth factor: a 
critical cytokine in tumor angiogenesis and a potential target for diagnosis and 
therapy. J Clin Oncol, 2002. 20(21): p. 4368-80. 
133. Dvorak, H.F., Rous-Whipple Award Lecture. How tumors make bad blood 
vessels and stroma. Am J Pathol, 2003. 162(6): p. 1747-57. 
134. Brown, L.F., et al., Expression of vascular permeability factor (vascular 
endothelial growth factor) by epidermal keratinocytes during wound healing. J 
Exp Med, 1992. 176(5): p. 1375-9. 
135. Dvorak, H.F., et al., Fibrin containing gels induce angiogenesis. Implications for 
tumor stroma generation and wound healing. Lab Invest, 1987. 57(6): p. 673-86. 
136. Martin, P., Wound healing--aiming for perfect skin regeneration. Science, 1997. 
276(5309): p. 75-81. 
137. Dong, X., S. Mao, and H. Wen, Upregulation of proinflammatory genes in skin 
lesions may be the cause of keloid formation (Review). Biomed Rep, 2013. 1(6): 
p. 833-836. 
138. Gauglitz, G.G., et al., Hypertrophic scarring and keloids: pathomechanisms and 
current and emerging treatment strategies. Mol Med, 2011. 17(1-2): p. 113-25. 
139. Tuan, T.L., et al., Increased plasminogen activator inhibitor-1 in keloid fibroblasts 
may account for their elevated collagen accumulation in fibrin gel cultures. Am J 
Pathol, 2003. 162(5): p. 1579-89. 
140. Tang, W., et al., Integrated proteotranscriptomics of breast cancer reveals 
globally increased protein-mRNA concordance associated with subtypes and 
survival. Genome Medicine, 2018. 10(1): p. 94. 
141. Fuentes-Duculan, J., et al., Aberrant connective tissue differentiation towards 
cartilage and bone underlies human keloids in African Americans. Exp Dermatol, 
2017. 26(8): p. 721-727. 
 64 
142. Li, S., et al., Plasminogen activator inhibitor-1 in cancer research. Biomed 
Pharmacother, 2018. 105: p. 83-94. 
143. Chalmers, R.L., The evidence for the role of transforming growth factor-beta in 
the formation of abnormal scarring. Int Wound J, 2011. 8(3): p. 218-23. 
144. Barcellos-Hoff, M.H. and R.J. Akhurst, Transforming growth factor-beta in breast 
cancer: too much, too late. Breast Cancer Res, 2009. 11(1): p. 202. 
145. Zarzynska, J.M., Two Faces of TGF-Beta1 in Breast Cancer. Mediators of 
Inflammation, 2014. 2014: p. 141747. 
146. Ashcroft, G.S. and S.J. Mills, Androgen receptor–mediated inhibition of 
cutaneous wound healing. The Journal of Clinical Investigation, 2002. 110(5): p. 
615-624. 
147. Wu, L., et al., Transforming growth factor-beta1 fails to stimulate wound healing 
and impairs its signal transduction in an aged ischemic ulcer model: importance 
of oxygen and age. Am J Pathol, 1999. 154(1): p. 301-9. 
148. LeFlore, I.C., Misconceptions regarding elective plastic surgery in the black 
patient. J Natl Med Assoc, 1980. 72(10): p. 947-8. 
149. Marneros, A.G., et al., Clinical genetics of familial keloids. Arch Dermatol, 2001. 
137(11): p. 1429-34. 
150. Assi, H.A., et al., Epidemiology and prognosis of breast cancer in young women. 
J Thorac Dis, 2013. 5 Suppl 1(Suppl 1): p. S2-8. 
151. Narod, S.A., Breast cancer in young women. Nat Rev Clin Oncol, 2012. 9(8): p. 
460-70. 
152. Newman, L.A., Breast cancer disparities: high-risk breast cancer and African 
ancestry. Surg Oncol Clin N Am, 2014. 23(3): p. 579-92. 
153. Dunn, B.K., et al., Health disparities in breast cancer: biology meets 
socioeconomic status. Breast Cancer Res Treat, 2010. 121(2): p. 281-92. 
 65 
154. Gimble, J.M., A.J. Katz, and B.A. Bunnell, Adipose-derived stem cells for 
regenerative medicine. Circ Res, 2007. 100(9): p. 1249-60. 
155. Bourin, P., et al., Stromal cells from the adipose tissue-derived stromal vascular 
fraction and culture expanded adipose tissue-derived stromal/stem cells: a 
joint statement of the International Federation for Adipose Therapeutics and 
Science (IFATS) and the International Society for Cellular Therapy (ISCT). 
Cytotherapy, 2013. 15(6): p. 641-8. 
156. McIntosh, K.R., et al., Evolution and future prospects of adipose-derived 
immunomodulatory cell therapeutics. Expert Rev Clin Immunol, 2013. 9(2): p. 
175-84. 
157. Li, X., et al., Harnessing the secretome of adipose-derived stem cells in the 
treatment of ischemic heart diseases. Stem Cell Research & Therapy, 2019. 
10(1): p. 196. 
158. Baraniak, P.R. and T.C. McDevitt, Stem cell paracrine actions and tissue 
regeneration. Regen Med, 2010. 5(1): p. 121-43. 
159. Dubey, N.K., et al., Revisiting the Advances in Isolation, Characterization and 
Secretome of Adipose-Derived Stromal/Stem Cells. Int J Mol Sci, 2018. 19(8). 
160. Bussolino, F., et al., In vitro and in vivo activation of endothelial cells by colony-
stimulating factors. J Clin Invest, 1991. 87(3): p. 986-95. 
161. Rehman, J., et al., Secretion of angiogenic and antiapoptotic factors by human 
adipose stromal cells. Circulation, 2004. 109(10): p. 1292-8. 
162. Zimmerlin, L., et al., Regenerative therapy and cancer: in vitro and in vivo studies 
of the interaction between adipose-derived stem cells and breast cancer cells 
from clinical isolates. Tissue Eng Part A, 2011. 17(1-2): p. 93-106. 
163. Voog, J. and D.L. Jones, Stem cells and the niche: a dynamic duo. Cell Stem 
Cell, 2010. 6(2): p. 103-15. 
164. Mazini, L., et al., Hopes and Limits of Adipose-Derived Stem Cells (ADSCs) and 
Mesenchymal Stem Cells (MSCs) in Wound Healing. Int J Mol Sci, 2020. 21(4). 
 66 
165. Nourian Dehkordi, A., et al., Skin tissue engineering: wound healing based on 
stem-cell-based therapeutic strategies. Stem Cell Research & Therapy, 2019. 
10(1): p. 111. 
166. Hyldig, K., et al., Implications of Extracellular Matrix Production by Adipose 
Tissue-Derived Stem Cells for Development of Wound Healing Therapies. Int J 
Mol Sci, 2017. 18(6). 
167. Baharlou, R., et al., Human adipose tissue-derived mesenchymal stem cells in 
rheumatoid arthritis: Regulatory effects on peripheral blood mononuclear cells 
activation. Int Immunopharmacol, 2017. 47: p. 59-69. 
168. Nowicka, A., et al., Human omental-derived adipose stem cells increase ovarian 
cancer proliferation, migration, and chemoresistance. PLoS One, 2013. 8(12): p. 
e81859. 
169. Razmkhah, M., et al., Adipose derived stem cells (ASCs) isolated from breast 
cancer tissue express IL-4, IL-10 and TGF-β1 and upregulate expression of 
regulatory molecules on T cells: do they protect breast cancer cells from the 
immune response? Cell Immunol, 2011. 266(2): p. 116-22. 
170. Ning, H., et al., Insulin growth factor signaling mediates neuron-like differentiation 
of adipose-tissue-derived stem cells. Differentiation, 2008. 76(5): p. 488-94. 
171. Nakagami, H., et al., Adipose tissue-derived stromal cells as a novel option for 
regenerative cell therapy. J Atheroscler Thromb, 2006. 13(2): p. 77-81. 
172. Song, Y.H., et al., VEGF is critical for spontaneous differentiation of stem cells 
into cardiomyocytes. Biochem Biophys Res Commun, 2007. 354(4): p. 999-1003. 
173. Kim, W.S., et al., Wound healing effect of adipose-derived stem cells: a critical 
role of secretory factors on human dermal fibroblasts. J Dermatol Sci, 2007. 
48(1): p. 15-24. 
174. Xiong, L., et al., In vitro N-acetyl-L-cysteine promotes proliferation and 
suppresses interleukin-8 expression in adipose-derived stem cells. Aesthetic 
Plast Surg, 2012. 36(5): p. 1260-5. 
 67 
175. Lin, X.H., et al., [Effects of adipose-derived stem cells transplantation on the 
neuronal apoptosis and the expression of Bcl-2 and caspase-12 in the brain post 
focal cerebral ischemia in rats]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2011. 
27(1): p. 40-3. 
176. Sabol, R.A., et al., Adipose Stem Cells and Cancer: Concise Review. Stem Cells, 
2019. 37(10): p. 1261-1266. 
177. Yancopoulos, G.D., et al., Vascular-specific growth factors and blood vessel 
formation. Nature, 2000. 407(6801): p. 242-8. 
178. Heo, S.C., et al., Tumor necrosis factor-α-activated human adipose tissue-
derived mesenchymal stem cells accelerate cutaneous wound healing through 
paracrine mechanisms. J Invest Dermatol, 2011. 131(7): p. 1559-67. 
179. Li, P. and X. Guo, A review: therapeutic potential of adipose-derived stem cells in 
cutaneous wound healing and regeneration. Stem Cell Res Ther, 2018. 9(1): p. 
302. 
180. Ma, Y., et al., IL-6, IL-8 and TNF-α levels correlate with disease stage in breast 
cancer patients. Adv Clin Exp Med, 2017. 26(3): p. 421-426. 
181. Gentile, P. and S. Garcovich, Concise Review: Adipose-Derived Stem Cells 
(ASCs) and Adipocyte-Secreted Exosomal microRNA (A-SE-miR) Modulate 
Cancer Growth and proMote Wound Repair. J Clin Med, 2019. 8(6). 
182. Strong, A.L., et al., Concise review: The obesity cancer paradigm: exploration of 
the interactions and crosstalk with adipose stem cells. Stem Cells, 2015. 33(2): p. 
318-26. 
183. Simoni-Nieves, A., et al., GDF11 Implications in Cancer Biology and Metabolism. 
Facts and Controversies. Frontiers in Oncology, 2019. 9(1039). 
184. Lombardi, F., et al., Secretome of Adipose Tissue-Derived Stem Cells (ASCs) as 
a Novel Trend in Chronic Non-Healing Wounds: An Overview of Experimental In 
Vitro and In Vivo Studies and Methodological Variables. International journal of 
molecular sciences, 2019. 20(15): p. 3721. 
 68 
185. Dufrane, D., Impact of Age on Human Adipose Stem Cells for Bone Tissue 
Engineering. Cell Transplant, 2017. 26(9): p. 1496-1504. 
186. Ruthenborg, R.J., et al., Regulation of wound healing and fibrosis by hypoxia and 
hypoxia-inducible factor-1. Mol Cells, 2014. 37(9): p. 637-43. 
187. Sánchez-Jiménez, F., et al., Obesity and Breast Cancer: Role of Leptin. Front 
Oncol, 2019. 9: p. 596. 
188. Tadokoro, S., et al., Leptin promotes wound healing in the skin. PLoS One, 2015. 
10(3): p. e0121242. 
189. Pandey, A.C., et al., MicroRNA profiling reveals age-dependent differential 
expression of nuclear factor κB and mitogen-activated protein kinase in adipose 
and bone marrow-derived human mesenchymal stem cells. Stem Cell Res Ther, 
2011. 2(6): p. 49. 
190. Trivanović, D., et al., Characteristics of human adipose mesenchymal stem cells 
isolated from healthy and cancer affected people and their interactions with 
human breast cancer cell line MCF-7 in vitro. Cell Biol Int, 2014. 38(2): p. 254-65. 
191. Bagó, J.R., et al., Endothelial differentiation of adipose tissue-derived 
mesenchymal stromal cells in glioma tumors: implications for cell-based therapy. 
Mol Ther, 2013. 21(9): p. 1758-66. 
192. Eterno, V., et al., Adipose-derived Mesenchymal Stem Cells (ASCs) may favour 
breast cancer recurrence via HGF/c-Met signaling. Oncotarget, 2014. 5(3): p. 
613-33. 
193. Castells, M., et al., Implication of tumor microenvironment in chemoresistance: 
tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci, 
2012. 13(8): p. 9545-71. 
194. Nyberg, P., T. Salo, and R. Kalluri, Tumor microenvironment and angiogenesis. 
Front Biosci, 2008. 13: p. 6537-53. 
195. Delort, L., et al., Hormonal Therapy Resistance and Breast Cancer: Involvement 
of Adipocytes and Leptin. Nutrients, 2019. 11(12). 
 69 
196. Strong, A.L., et al., Human Adipose Stromal/Stem Cells from Obese Donors 
Show Reduced Efficacy in Halting Disease Progression in the Experimental 
Autoimmune Encephalomyelitis Model of Multiple Sclerosis. Stem Cells, 2016. 
34(3): p. 614-26. 
197. Strong, A.L., et al., Leptin produced by obese adipose stromal/stem cells 
enhances proliferation and metastasis of estrogen receptor positive breast 
cancers. Breast Cancer Res, 2015. 17(1): p. 112. 
198. Strong, A.L., et al., Obesity associated alterations in the biology of adipose stem 
cells mediate enhanced tumorigenesis by estrogen dependent pathways. Breast 
Cancer Res, 2013. 15(5): p. R102. 
199. Nicola, M.H., et al., Breast cancer micrometastases: different interactions of 
carcinoma cells with normal and cancer patients' bone marrow stromata. Clin 
Exp Metastasis, 2003. 20(5): p. 471-9. 
200. Hombauer, H. and J.J. Minguell, Selective interactions between epithelial tumour 
cells and bone marrow mesenchymal stem cells. Br J Cancer, 2000. 82(7): p. 
1290-6. 
201. Arwert, E.N., E. Hoste, and F.M. Watt, Epithelial stem cells, wound healing and 
cancer. Nature Reviews Cancer, 2012. 12(3): p. 170-180. 
202. Wu, L.W., et al., Donor age negatively affects the immunoregulatory properties of 
both adipose and bone marrow derived mesenchymal stem cells. Transpl 
Immunol, 2014. 30(4): p. 122-7. 
203. Cianfarani, F., et al., Diabetes impairs adipose tissue-derived stem cell function 
and efficiency in promoting wound healing. Wound Repair Regen, 2013. 21(4): p. 
545-53. 
204. Bunnell, B.A., et al., Adipose-derived stem cells: isolation, expansion and 
differentiation. Methods, 2008. 45(2): p. 115-20. 
205. Lu, P., V.M. Weaver, and Z. Werb, The extracellular matrix: a dynamic niche in 
cancer progression. J Cell Biol, 2012. 196(4): p. 395-406. 
 70 
206. Sun, Y., et al., Rescuing replication and osteogenesis of aged mesenchymal 
stem cells by exposure to a young extracellular matrix. Faseb j, 2011. 25(5): p. 
1474-85. 
207. Choudhery, M.S., et al., Donor age negatively impacts adipose tissue-derived 
mesenchymal stem cell expansion and differentiation. J Transl Med, 2014. 12: p. 
8. 
208. Kornicka, K., et al., The Effect of Age on Osteogenic and Adipogenic 
Differentiation Potential of Human Adipose Derived Stromal Stem Cells (hASCs) 
and the Impact of Stress Factors in the Course of the Differentiation Process. 
Oxid Med Cell Longev, 2015. 2015: p. 309169. 
209. Rao, M.S. and M.P. Mattson, Stem cells and aging: expanding the possibilities. 
Mech Ageing Dev, 2001. 122(7): p. 713-34. 
210. Krause, D.S., et al., Multi-organ, multi-lineage engraftment by a single bone 
marrow-derived stem cell. Cell, 2001. 105(3): p. 369-77. 
211. Ortiz, L.A., et al., Interleukin 1 receptor antagonist mediates the antiinflammatory 
and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl 
Acad Sci U S A, 2007. 104(26): p. 11002-7. 
212. ; Available from: breastcancer.org. 
213. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2019. CA Cancer J Clin, 
2019. 69(1): p. 7-34. 
214. Fletcher, S.J., et al., Human breast adipose tissue: characterization of factors 
that change during tumor progression in human breast cancer. J Exp Clin Cancer 
Res, 2017. 36(1): p. 26. 
215. Yeh, W.L., C.F. Tsai, and D.R. Chen, Peri-foci adipose-derived stem cells 
promote chemoresistance in breast cancer. Stem Cell Res Ther, 2017. 8(1): p. 
177. 
216. Bhowmick, N.A., E.G. Neilson, and H.L. Moses, Stromal fibroblasts in cancer 
initiation and progression. Nature, 2004. 432(7015): p. 332-7. 
 71 
217. Orimo, A. and R.A. Weinberg, Stromal fibroblasts in cancer: a novel tumor-
promoting cell type. Cell Cycle, 2006. 5(15): p. 1597-601. 
218. Recouvreux, S., et al., Microenvironment and endocrine resistance in breast 
cancer: Friend or foe? World J Clin Oncol, 2015. 6(6): p. 207-11. 
219. Muehlberg, F.L., et al., Tissue-resident stem cells promote breast cancer growth 
and metastasis. Carcinogenesis, 2009. 30(4): p. 589-97. 
220. Rhodes, L.V., et al., Effects of human mesenchymal stem cells on ER-positive 
human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. 
Mol Cancer, 2010. 9: p. 295. 
221. Bissell, M.J. and D. Radisky, Putting tumours in context. Nat Rev Cancer, 2001. 
1(1): p. 46-54. 
222. Hu, M. and K. Polyak, Molecular characterisation of the tumour 
microenvironment in breast cancer. Eur J Cancer, 2008. 44(18): p. 2760-5. 
223. Liotta, L.A. and E.C. Kohn, The microenvironment of the tumour-host interface. 
Nature, 2001. 411(6835): p. 375-9. 
224. Goto, H., et al., Adipose-derived stem cells enhance human breast cancer 
growth and cancer stem cell-like properties through adipsin. Oncogene, 2019. 
38(6): p. 767-779. 
225. Lee, C.C., F. Ye, and A.F. Tarantal, Comparison of growth and differentiation of 
fetal and adult rhesus monkey mesenchymal stem cells. Stem Cells Dev, 2006. 
15(2): p. 209-20. 
226. Choudhery, M.S., et al., Comparison of human mesenchymal stem cells derived 
from adipose and cord tissue. Cytotherapy, 2013. 15(3): p. 330-43. 
227. Freese, K.E., et al., Adipose-derived stems cells and their role in human cancer 
development, growth, progression, and metastasis: a systematic review. Cancer 
Res, 2015. 75(7): p. 1161-8. 
 72 
228. Razmkhah, M., et al., Expression profile of IL-8 and growth factors in breast 
cancer cells and adipose-derived stem cells (ASCs) isolated from breast 
carcinoma. Cell Immunol, 2010. 265(1): p. 80-5. 
229. Huang, G., et al., Functional and Biomimetic Materials for Engineering of the 
Three-Dimensional Cell Microenvironment. Chem Rev, 2017. 117(20): p. 12764-
12850. 
230. Watt, F.M. and W.T. Huck, Role of the extracellular matrix in regulating stem cell 
fate. Nat Rev Mol Cell Biol, 2013. 14(8): p. 467-73. 
231. Morrison, S.J. and A.C. Spradling, Stem cells and niches: mechanisms that 
promote stem cell maintenance throughout life. Cell, 2008. 132(4): p. 598-611. 
232. Discher, D.E., P. Janmey, and Y.L. Wang, Tissue cells feel and respond to the 
stiffness of their substrate. Science, 2005. 310(5751): p. 1139-43. 
233. Pelham, R.J., Jr. and Y. Wang, Cell locomotion and focal adhesions are 
regulated by substrate flexibility. Proc Natl Acad Sci U S A, 1997. 94(25): p. 
13661-5. 
234. Oh, J., Y.D. Lee, and A.J. Wagers, Stem cell aging: mechanisms, regulators and 
therapeutic opportunities. Nat Med, 2014. 20(8): p. 870-80. 
235. Kular, J.K., S. Basu, and R.I. Sharma, The extracellular matrix: Structure, 
composition, age-related differences, tools for analysis and applications for tissue 
engineering. J Tissue Eng, 2014. 5: p. 2041731414557112. 
236. Kurtz, A. and S.J. Oh, Age related changes of the extracellular matrix and stem 
cell maintenance. Prev Med, 2012. 54 Suppl: p. S50-6. 
237. Choi, H.R., et al., Restoration of senescent human diploid fibroblasts by 
modulation of the extracellular matrix. Aging Cell, 2011. 10(1): p. 148-57. 
238. Midwood, K.S., L.V. Williams, and J.E. Schwarzbauer, Tissue repair and the 
dynamics of the extracellular matrix. Int J Biochem Cell Biol, 2004. 36(6): p. 
1031-7. 
 73 
239. Raghow, R., The role of extracellular matrix in postinflammatory wound healing 
and fibrosis. Faseb j, 1994. 8(11): p. 823-31. 
240. Dvorak, H.F., Tumors: wounds that do not heal. Similarities between tumor 
stroma generation and wound healing. N Engl J Med, 1986. 315(26): p. 1650-9. 
241. Sharpless, N.E. and R.A. DePinho, How stem cells age and why this makes us 
grow old. Nat Rev Mol Cell Biol, 2007. 8(9): p. 703-13. 
242. Lähteenvuo, J. and A. Rosenzweig, Effects of aging on angiogenesis. Circ Res, 
2012. 110(9): p. 1252-64. 
243. Donato, A.J., et al., Aging is associated with greater nuclear NF kappa B, 
reduced I kappa B alpha, and increased expression of proinflammatory cytokines 
in vascular endothelial cells of healthy humans. Aging Cell, 2008. 7(6): p. 805-12. 
244. Prockop, D.J. and J.Y. Oh, Mesenchymal stem/stromal cells (MSCs): role as 
guardians of inflammation. Mol Ther, 2012. 20(1): p. 14-20. 
245. Grossman, R.L., et al., Toward a Shared Vision for Cancer Genomic Data. N 
Engl J Med, 2016. 375(12): p. 1109-12. 
246. Dennis, G., Jr., et al., DAVID: Database for Annotation, Visualization, and 
Integrated Discovery. Genome Biol, 2003. 4(5): p. P3. 
247. Jézéquel, P., et al., bc-GenExMiner 3.0: new mining module computes breast 
cancer gene expression correlation analyses. Database (Oxford), 2013. 2013: p. 
bas060. 
248. Koboldt, D.C., et al., Comprehensive molecular portraits of human breast 
tumours. Nature, 2012. 490(7418): p. 61-70. 
249. Nagy, Á., et al., Validation of miRNA prognostic power in hepatocellular 
carcinoma using expression data of independent datasets. Sci Rep, 2018. 8(1): 
p. 9227. 
250. Aran, D., Z. Hu, and A.J. Butte, xCell: digitally portraying the tissue cellular 
heterogeneity landscape. Genome Biol, 2017. 18(1): p. 220. 
 74 
251. Goldman, M., et al., The UCSC Cancer Genomics Browser: update 2013. 
Nucleic Acids Res, 2013. 41(Database issue): p. D949-54. 
252. Sanborn, J.Z., et al., The UCSC Cancer Genomics Browser: update 2011. 
Nucleic Acids Res, 2011. 39(Database issue): p. D951-9. 
253. Vaske, C.J., et al., Inference of patient-specific pathway activities from multi-
dimensional cancer genomics data using PARADIGM. Bioinformatics, 2010. 
26(12): p. i237-45. 
254. Renema, N., et al., RANK-RANKL signalling in cancer. Biosci Rep, 2016. 36(4). 
255. Belgodere, J.A., et al., Engineering Breast Cancer Microenvironments and 3D 
Bioprinting. Front Bioeng Biotechnol, 2018. 6: p. 66. 
256. DeNardo, D.G., et al., Leukocyte complexity predicts breast cancer survival and 
functionally regulates response to chemotherapy. Cancer Discov, 2011. 1(1): p. 
54-67. 
257. Gilbert, L.A. and M.T. Hemann, DNA damage-mediated induction of a 
chemoresistant niche. Cell, 2010. 143(3): p. 355-66. 
258. Condeelis, J. and J.W. Pollard, Macrophages: obligate partners for tumor cell 
migration, invasion, and metastasis. Cell, 2006. 124(2): p. 263-6. 
259. Shree, T., et al., Macrophages and cathepsin proteases blunt chemotherapeutic 
response in breast cancer. Genes Dev, 2011. 25(23): p. 2465-79. 
260. Tan, W., et al., Tumour-infiltrating regulatory T cells stimulate mammary cancer 
metastasis through RANKL-RANK signalling. Nature, 2011. 470(7335): p. 548-
53. 
261. Oskarsson, T., Extracellular matrix components in breast cancer progression and 
metastasis. Breast, 2013. 22 Suppl 2: p. S66-72. 
262. Insua-Rodríguez, J. and T. Oskarsson, The extracellular matrix in breast cancer. 
Adv Drug Deliv Rev, 2016. 97: p. 41-55. 
 75 
263. Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 100(1): p. 
57-70. 
264. Bergamaschi, A., et al., Extracellular matrix signature identifies breast cancer 
subgroups with different clinical outcome. J Pathol, 2008. 214(3): p. 357-67. 
265. Helleman, J., et al., Association of an extracellular matrix gene cluster with breast 
cancer prognosis and endocrine therapy response. Clin Cancer Res, 2008. 
14(17): p. 5555-64. 
266. van 't Veer, L.J., et al., Gene expression profiling predicts clinical outcome of 
breast cancer. Nature, 2002. 415(6871): p. 530-6. 
267. Wang, Y., et al., Gene-expression profiles to predict distant metastasis of lymph-
node-negative primary breast cancer. Lancet, 2005. 365(9460): p. 671-9. 
268. Perou, C.M., et al., Molecular portraits of human breast tumours. Nature, 2000. 
406(6797): p. 747-52. 
269. Li, J. and N. Sidell, Growth-related oncogene produced in human breast cancer 
cells and regulated by Syk protein-tyrosine kinase. Int J Cancer, 2005. 117(1): p. 
14-20. 
270. Bièche, I., et al., CXC chemokines located in the 4q21 region are up-regulated in 
breast cancer. Endocr Relat Cancer, 2007. 14(4): p. 1039-52. 
271. Waugh, D.J. and C. Wilson, The interleukin-8 pathway in cancer. Clin Cancer 
Res, 2008. 14(21): p. 6735-41. 
272. Mira, E., et al., A role for chemokine receptor transactivation in growth factor 
signaling. EMBO Rep, 2001. 2(2): p. 151-6. 
273. Hall, J.M. and K.S. Korach, Stromal cell-derived factor 1, a novel target of 
estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian 
and breast cancer cells. Mol Endocrinol, 2003. 17(5): p. 792-803. 
274. Sauvé, K., et al., Positive feedback activation of estrogen receptors by the 
CXCL12-CXCR4 pathway. Cancer Res, 2009. 69(14): p. 5793-800. 
 76 
275. Corcoran, K.E., et al., Mesenchymal stem cells in early entry of breast cancer 
into bone marrow. PLoS One, 2008. 3(6): p. e2563. 
276. Cristino, S., et al., Expression of CXC chemokines and their receptors is 
modulated during chondrogenic differentiation of human mesenchymal stem cells 
grown in three-dimensional scaffold: evidence in native cartilage. Tissue Eng 
Part A, 2008. 14(1): p. 97-105. 
277. Hermann, P.C., et al., Distinct populations of cancer stem cells determine tumor 
growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 2007. 
1(3): p. 313-23. 
278. Singh, S., et al., CXCL12-CXCR4 signalling axis confers gemcitabine resistance 
to pancreatic cancer cells: a novel target for therapy. Br J Cancer, 2010. 103(11): 
p. 1671-9. 
279. Pruneri, G., A. Vingiani, and C. Denkert, Tumor infiltrating lymphocytes in early 
breast cancer. Breast, 2018. 37: p. 207-214. 
280. Ali, H.R., et al., Patterns of Immune Infiltration in Breast Cancer and Their 
Clinical Implications: A Gene-Expression-Based Retrospective Study. PLoS Med, 
2016. 13(12): p. e1002194. 
281. Jin, Y.W. and P. Hu, Tumor-Infiltrating CD8 T Cells Predict Clinical Breast 
Cancer Outcomes in Young Women. Cancers (Basel), 2020. 12(5). 
282. Schipper, B.M., et al., Regional anatomic and age effects on cell function of 
human adipose-derived stem cells. Ann Plast Surg, 2008. 60(5): p. 538-44. 
283. Bustos, M.L., et al., Aging mesenchymal stem cells fail to protect because of 
impaired migration and antiinflammatory response. Am J Respir Crit Care Med, 
2014. 189(7): p. 787-98. 
284. Antoon, J.W., et al., Inhibition of p38 mitogen-activated protein kinase alters 
microRNA expression and reverses epithelial-to-mesenchymal transition. Int J 
Oncol, 2013. 42(4): p. 1139-50. 
 77 
285. To, S.Q., et al., Estradiol regulates Tumor Necrosis Factor-α expression and 
secretion in Estrogen Receptor positive breast cancer cells. Mol Cell Endocrinol, 
2014. 394(1-2): p. 21-8. 
286. Szlosarek, P.W. and F.R. Balkwill, Tumour necrosis factor alpha: a potential 
target for the therapy of solid tumours. Lancet Oncol, 2003. 4(9): p. 565-73. 
287. Shou, J., et al., Mechanisms of tamoxifen resistance: increased estrogen 
receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer 
Inst, 2004. 96(12): p. 926-35. 
288. Sabnis, G.J., et al., The role of growth factor receptor pathways in human breast 
cancer cells adapted to long-term estrogen deprivation. Cancer Res, 2005. 65(9): 
p. 3903-10. 
289. Fan, P., et al., Long-term treatment with tamoxifen facilitates translocation of 
estrogen receptor alpha out of the nucleus and enhances its interaction with 
EGFR in MCF-7 breast cancer cells. Cancer Res, 2007. 67(3): p. 1352-60. 
290. Britton, D.J., et al., Bidirectional cross talk between ERalpha and EGFR 
signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res 
Treat, 2006. 96(2): p. 131-46. 
291. Fan, P., et al., A molecular model for the mechanism of acquired tamoxifen 
resistance in breast cancer. Eur J Cancer, 2014. 50(16): p. 2866-76. 
292. Ribas, R., et al., Identification of chemokine receptors as potential modulators of 
endocrine resistance in oestrogen receptor-positive breast cancers. Breast 
Cancer Res, 2014. 16(5): p. 447. 
293. Stender, J.D., et al., Structural and Molecular Mechanisms of Cytokine-Mediated 
Endocrine Resistance in Human Breast Cancer Cells. Mol Cell, 2017. 65(6): p. 
1122-1135.e5. 
294. Ben-Neriah, Y. and M. Karin, Inflammation meets cancer, with NF-κB as the 
matchmaker. Nat Immunol, 2011. 12(8): p. 715-23. 
 78 
295. Zhou, Y., et al., Enhanced NF kappa B and AP-1 transcriptional activity 
associated with antiestrogen resistant breast cancer. BMC Cancer, 2007. 7: p. 
59. 
296. Wang, X., et al., Oestrogen signalling inhibits invasive phenotype by repressing 
RelB and its target BCL2. Nat Cell Biol, 2007. 9(4): p. 470-8. 
297. Adamson, A.D., et al., Human prolactin gene promoter regulation by estrogen: 
convergence with tumor necrosis factor-alpha signaling. Endocrinology, 2008. 
149(2): p. 687-94. 
298. Rubio, M.F., et al., TNF-alpha enhances estrogen-induced cell proliferation of 
estrogen-dependent breast tumor cells through a complex containing nuclear 
factor-kappa B. Oncogene, 2006. 25(9): p. 1367-77. 
299. Zhou, Y., et al., Activation of nuclear factor-kappaB (NFkappaB) identifies a high-
risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol, 2005. 
37(5): p. 1130-44. 
300. deGraffenried, L.A., et al., NF-kappa B inhibition markedly enhances sensitivity of 
resistant breast cancer tumor cells to tamoxifen. Ann Oncol, 2004. 15(6): p. 885-
90. 
301. Riggins, R.B., et al., The nuclear factor kappa B inhibitor parthenolide restores 
ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant 
breast cancer cells. Mol Cancer Ther, 2005. 4(1): p. 33-41. 
302. Biswas, D.K., et al., NF-kappa B activation in human breast cancer specimens 
and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A, 2004. 
101(27): p. 10137-42. 
303. Nakshatri, H., et al., Constitutive activation of NF-kappaB during progression of 
breast cancer to hormone-independent growth. Mol Cell Biol, 1997. 17(7): p. 
3629-39. 
304. Baumgarten, S.C. and J. Frasor, Minireview: Inflammation: an instigator of more 
aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol, 
2012. 26(3): p. 360-71. 
 79 
305. Zhu, P., et al., Macrophage/cancer cell interactions mediate hormone resistance 
by a nuclear receptor derepression pathway. Cell, 2006. 124(3): p. 615-29. 
306. Sas, L., et al., The interaction between ER and NFκB in resistance to endocrine 
therapy. Breast Cancer Res, 2012. 14(4): p. 212. 
307. De Bosscher, K., W. Vanden Berghe, and G. Haegeman, Cross-talk between 
nuclear receptors and nuclear factor kappaB. Oncogene, 2006. 25(51): p. 6868-
86. 
308. Bennett, L., et al., High IKKα expression is associated with reduced time to 
recurrence and cancer specific survival in oestrogen receptor (ER)-positive 
breast cancer. Int J Cancer, 2017. 140(7): p. 1633-1644. 
309. Boehm, J.S., et al., Integrative genomic approaches identify IKBKE as a breast 
cancer oncogene. Cell, 2007. 129(6): p. 1065-79. 
310. Brzozowski, A.M., et al., Molecular basis of agonism and antagonism in the 
oestrogen receptor. Nature, 1997. 389(6652): p. 753-8. 
311. Xu, L., C.K. Glass, and M.G. Rosenfeld, Coactivator and corepressor complexes 
























Katie Hamel, born in Covington, Louisiana, completed her Bachelor of Science in 
Biological Sciences from Louisiana State University (LSU) in May 2011. She graduated 
with Upper Division Honors Distinction and was awarded multiple university-based 
scholarships including Tiger Athletic Award Scholarship, Flagship Ph.D. Graduate 
Assistantship, and Graduate School Dean’s Travel Award. Katie plans to graduate with 
her Ph.D. in Biological Engineering from LSU in May 2021 and continue to work in stem 
cell biology at Obatala Sciences. Her research focused on breast cancer and adipose-
derived stem/stromal cell interactions in Dr. Elizabeth Martin’s lab.  
 
 
 
